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A B S T R A C T
Background
Despite antiretroviral therapy (ART) being widely available, HIV continues to cause substantial illness and premature death in low-
and-middle-income countries. High rates of loss to follow-up after HIV diagnosis can delay people starting ART. Starting ART within
seven days of HIV diagnosis (rapid ART initiation) could reduce loss to follow-up, improve virological suppression rates, and reduce
mortality.
Objectives
To assess the effects of interventions for rapid initiation of ART (defined as offering ART within seven days of HIV diagnosis) on
treatment outcomes and mortality in people living with HIV. We also aimed to describe the characteristics of rapid ART interventions
used in the included studies.
Search methods
We searchedCENTRAL, theCochrane Database of Systematic Reviews, MEDLINE, Embase, and four other databases up to 14 August
2018. There was no restriction on date, language, or publication status. We also searched ClinicalTrials.gov and the World Health
Organization (WHO) International Clinical Trials Registry Platform, and websites for unpublished literature, including conference
abstracts.
Selection criteria
We included randomized controlled trials (RCTs) that compared rapid ART versus standard care in people living with HIV. Children,
adults, and adolescents from any setting were eligible for inclusion.
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Data collection and analysis
Two review authors independently assessed the eligibility of the studies identified in the search, assessed the risk of bias and extracted
data. The primary outcomes were mortality and virological suppression at 12 months. We have presented all outcomes using risk ratios
(RR), with 95% confidence intervals (CIs). Where appropriate, we pooled the results in meta-analysis. We assessed the certainty of the
evidence using the GRADE approach.
Main results
We included seven studies with 18,011 participants in the review. All studies were carried out in low- and middle-income countries in
adults aged 18 years old or older. Only one study included pregnant women.
In all the studies, the rapid ART intervention was offered as part of a package that included several cointerventions targeting individuals,
health workers and health system processes delivered alongside rapid ART that aimed to facilitate uptake and adherence to ART.
Comparing rapid ART with standard initiation probably results in greater viral suppression at 12 months (RR 1.18, 95% CI 1.10 to
1.27; 2719 participants, 4 studies; moderate-certainty evidence) and better ART uptake at 12 months (RR 1.09, 95% CI 1.06 to 1.12;
3713 participants, 4 studies; moderate-certainty evidence), and may improve retention in care at 12 months (RR 1.22, 95% CI 1.11
to 1.35; 5001 participants, 6 studies; low-certainty evidence). Rapid ART initiation was associated with a lower mortality estimate,
however the CIs included no effect when compared to standard of care (RR 0.72, 95% CI 0.51 to 1.01; 5451 participants, 7 studies;
very low-certainty evidence). It is uncertain whether rapid ART has an effect on modification of ART treatment regimens as data are
lacking (RR 7.89, 95% CI 0.76 to 81.74; 977 participants, 2 studies; very low-certainty evidence). There was insufficient evidence to
draw conclusions on the occurrence of adverse events.
Authors’ conclusions
RCTs that include initiation of ART within one week of diagnosis appear to improve outcomes across the HIV treatment cascade in
low- and middle-income settings. The studies demonstrating these effects delivered rapid ART combined with several setting-specific
cointerventions. This highlights the need for pragmatic research to identify feasible packages that assure the effects seen in the trials
when delivered through complex health systems.
P L A I N L A N G U A G E S U M M A R Y
Effects of starting antiretroviral therapy within one week of diagnosis on people living with HIV
What is the aim of this review?
The aim was to determine whether starting antiretroviral therapy (ART) within one week of HIV diagnosis (rapid ART) resulted
in a lower risk of dying or better suppression of the virus in people’s blood than standard care; as well as studying the effect of this
intervention on whether people start taking ART and continue to be engaged in care after 12 months.
Key messages
Offering ART to people living with HIV (PLWH) within one week of diagnosis probably increases the number of people initiating the
therapy at 12 months and the number of PLWH whose virus has been suppressed in the blood at 12 months. It may also improve the
number of people who are still in contact with healthcare services at 12 months. We don’t know the effect this has on people dying.
We found that several other changes need to be made alongside rapid ART for services to achieve these outcomes.
What was studied in the review?
HIV is a leading cause of death worldwide. Although more people are taking ART than ever before, there is a large percentage of PLWH
who are not being treated. One of the reasons identified is the long period between being diagnosed with HIV and starting ART. Rapid
ART has been proposed as a way to increase the number of PLWH being started on ART and improve HIV-related outcomes.
What are the main results of the review?
We found seven studies that met the inclusion criteria of the review and assessed the effect of rapid ART on PLWH. Rapid ART
probably increases the number of people being initiated on ART at 12 months and the number of PLWH with no detectable virus
in their blood at 12 months (moderate-certainty evidence). Based on low-certainty evidence, rapid ART may increase the number of
PLWH being retained in care. We don’t know whether rapid ART has an effect on the number of deaths (very low-certainty evidence).
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We found that if healthcare services aim to offer ART within a week of diagnosis, changes to how these systems operate will need to be
made.
How up to date is the review?
We searched for relevant trials up to 14 August 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Rapid ART compared to standard care for people living with HIV
Patient or population: people living with HIV
Setting: any
Intervention: rapid ART
Comparison: standard care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard care Risk with rapid ART
Mortality at 12 months 44 per 1000 32 per 1000
(22 to 44)
RR 0.72
(0.51 to 1.01)
5451
(7 RCTs)
⊕©©©
Very lowa,b,c
We do not know if rapid
ART has an ef fect on
mortality af ter one year
of follow-up
Virological suppres-
sion at 12 months
506 per 1000 597 per 1000
(556 to 642)
RR 1.18
(1.10 to 1.27)
2719
(4 RCTs)d
⊕⊕⊕©
Moderatee,f,g,h
Rapid ART probably in-
creases the likelihood
of individuals being vi-
rally suppressed af ter
12 months
Retention in care at 12
months
538 per 1000 656 per 1000
(597 to 726)
RR 1.22
(1.11 to 1.35)
5001
(6 RCTs)
⊕⊕©©
Lowg,h,i,j
Rapid ART may improve
retent ion in care at 12
months.
Uptake of ART at 90
days
719 per 1000 942 per 1000
(848 to 1000)
RR 1.31
(1.18 to 1.45)
11,404
(4 RCTs)
⊕⊕©©
Lowh,k,l
Rapid ART may improve
uptake of ART at 90
days.
Uptake of ART at 12
months
870 per 1000 948 per 1000
(922 to 975)
RR 1.09
(1.06 to 1.12)
3713
(4 RCTs)
⊕⊕⊕©
Moderateh,k
Rapid ART probably im-
proves uptake of ART at
12 months.
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Treatment modifica-
tion
2 per 1000 23 per 1000
(4 to 119)
RR 7.89
(0.76 to 81.74)
977
(2 RCTs)
⊕©©©
Very lowm,n
We do not know the ef -
fect of rapid ART on
treatment modif icat ion
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviat ions: ART: ant iretroviral therapy; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one for risk of bias. All studies at high risk of bias due to large degree of attrit ion. As such the ef fect seen at
populat ion level is less clear.
bDowngraded by one for indirectness and qualitat ive heterogeneity. The largest studies, Elul 2017 and McNairy 2017, included
individuals who were not eligible for ant iretroviral therapy (ART) in denominators. The t ime of ART init iat ion varied across
studies, with studies of fering ART on the same day as diagnosis, within seven days or within 14 days. Cointervent ions also
varied signif icant ly between studies.
cDowngraded by one for imprecision. Broad CIs containing clinically signif icant benef it and no ef fect.
dOne study (McNairy 2017), measured virological suppression at 12 months only in those part icipants who received ART for
at least six months. We did not, therefore, include this study in the pooled est imate of ef fect.
eNot downgraded for risk of bias. Although all studies had a large degree of attrit ion, we assumed that part icipants lost to
follow-up were not receiving ART and, therefore, were not not virologically suppressed.
fNot downgraded for imprecision. Signif icant heterogeneity within the forest plot explained as McNairy 2017 calculated viral
suppression in a subpopulat ion of part icipants on ART for six months.
gDowngraded by one for indirectness. Cointervent ions delivered alongside rapid ART were dif ferent across studies. These
cointervent ions would af fect the outcome measured.
hNot downgraded for imprecision. Given that rapid ART is a populat ion-level intervent ion, we judge small increases in the
likelihood of uptake of ART to be clinically signif icant.
iDowngraded by one for risk of bias. All the studies were unblinded. Part icipants were aware of receiving a dif ferent standard
care, which could have made them more likely to be retained in care in the intervent ion arm.
jNot downgraded for inconsistency. There is moderate heterogeneity in the forest plot (I2 = 54%). However, this did not reduce
our certainty in the est imate of ef fect.
kDowngraded by one for risk of bias. All the studies were unblinded. The fact that part icipants and healthcare staf f knew the
allocat ion group could have inf luenced their performance, making them more likely to init iate ART.
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lDowngraded by one for inconsistency. There is high heterogeneity between studies. Although this is part ly explained by
the dif ferent designs (for example, Koenig 2017 and Rosen 2016 of fered ART on same day of diagnosis/ enrolment, whilst
Amanyire 2016 aimed to of fer it within 14 days of diagnoses), heterogeneity remains high when sim ilar studies are grouped
together.
mDowngraded by two for imprecision. Few events and broad CIs for absolute risk containing no clinically appreciable ef fects
and harm.
nDowngraded by one for qualitat ive and some stat ist ical heterogeneity. One study shows increased treatment modif icat ion
and the second shows no dif ference.
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B A C K G R O U N D
Description of the condition
At the end of 2017, there were approximately 36.9 million peo-
ple living with HIV (PLWH) worldwide, most of them in low-
and middle-income countries (LMICs) (WHO 2017). Although
expansion of antiretroviral therapy (ART) over the last decade has
halved HIV-related mortality (UNAIDS 2018), substantial chal-
lenges remain. In 2017, only 59% of PLWH were receiving ART
(UNAIDS 2018), with high attrition fromHIV services afterHIV
diagnosis (Govindasamy 2014; Losina 2010; Rosen 2011). This
is particularly relevant in sub-Saharan Africa, where it is estimated
that only 57% of those diagnosed with HIV are linked to care
(Kranzer 2012). Many affected individuals who disengage from
services during this period return only when they have deterio-
rated clinically and immunologically; resulting in high morbidity
and mortality after ART initiation (Fairall 2008; Grinsztejn 2014;
HMC 2015). Studies conducted in Ethiopia and sub-Saharan
Africa estimate that PLWH may wait over a month to start ART,
once eligibility is established (Bassett 2010; Lawn 2006; Reddy
2016; Teklu 2017). The reasons for these delays are complex and
involve a combination of structural, social, and psychological pa-
tient factors (Hoehn 2017; Wachira 2014), as well as poor health-
care infrastructure in some settings (Govindasamy 2012).
One proposed intervention for improving linkage and retention
of PLWH in HIV care is rapid ART initiation (starting ART as
soon as possible after testing HIV-positive, normally within seven
days) (Chan 2016; Pilcher 2017). PLWHpreviously attendedHIV
services several times for counselling and medical evaluation be-
fore starting treatment. Expediting ART initiation could poten-
tially lead to earlier viral suppression in the medium- and long-
term through improved uptake and adherence to ART as well as
through improved retention in care (Hoenigl 2016; Pilcher 2017;
Wilkinson 2015); what could result in lower overall mortality.
Recent guidelines now advocate for ART initiation within seven
days of HIV diagnosis (WHO 2018), with same-day initiation
for those patients who feel ready, but ART initiation should be
deferred if tuberculosis or cryptococcal meningitis is suspected or
confirmed, to avoid paradoxical worsening of the existing infec-
tion which can be fatal (Ford 2018; WHO 2018).
There remains, however, uncertainty about the long-term treat-
ment outcomes of rapid ART initiation (Mbonye 2016). Some
concerns include insufficient adherence counselling/education;
limited time to prepare psychologically for life with HIV and ART
(Black 2014; Kim 2016), pill burden due to other concurrent co
morbidities or conditions requiring urgent treatment (for exam-
ple, tuberculosis) (Nachega 2014); and immune reconstitution in-
flammatory syndrome (IRIS), especially in individuals with ad-
vanced disease (CD4 counts < 200 cells/mm³) (Uthman 2015),
all of which could impact on morbidity and engagement in care
(Hakim 2017). In addition, it is unclear what cointerventions fa-
cilitate long-term retention when rapid ART is provided within a
package of care during widespread implementation of this treat-
ment strategy.
In order to evaluate uptake, efficacy, safety, and to characterize
rapid ART interventions compared with delayed or routine ART
initiation we sought to consolidate findings from randomized con-
trolled trials (RCTs) evaluating the intervention.
Description of the intervention
The current standard care post-HIV diagnosis varies across set-
tings according to the local context (MacCarthy 2015). Countries
often include in their national guidelines structural and individ-
ual interventions aimed to improve linkage. These include: inte-
gration of services, point-of-care CD4 cell count, post-test coun-
selling, peer support, support with HIV disclosure, addressing
any psychosocial barriers identified and others (NASCOP 2016;
NCASC 2009; NDOHSA 2015; Wynberg 2014). Pre-ART care
routinely involves a baseline clinical and a psychosocial assessment
(MoH 2016) including; physical examination, laboratory tests,
opportunistic infection screening, nutritional status assessment,
counselling, health insurance evaluation, and education sessions
(NDOHSA 2015; Pilcher 2017). These assessments were previ-
ously carried out over several visits to HIV services, resulting in
delays in ART initiation, often for several weeks, after PLWHwere
considered eligible for ART (Lawn 2006; Teklu 2017).
For the purposes of this Cochrane Review, we define rapid ART
as offering the therapy within seven days after eligibility for ART.
According to current guidelines, PLWH are considered eligible for
ART on the same day as diagnosis unless they are found to have
signs or symptoms of opportunistic infections such as tuberculosis
or cryptococcal meningitis. With rapid ART, PLWH may receive
usual care, but some of the interventions that form part of pre-
ART care are delivered on the same day or within a few days
of HIV diagnosis. These include, among others, screening for
tuberculosis, physical examination and an initial counselling and
education session (Labhardt 2016; Pilcher 2017; Rosen 2016).
How the intervention might work
Delaying the initiation of ART has been identified in the literature
as a major contributor to disengagement, particularly in LMICs
(Govindasamy 2014), and rapid ART has the potential to improve
linkage and retention in HIV care on several levels; the simplifi-
cation and reduction in number of unnecessary clinic visits could
help PLWH to overcome financial and logistic barriers in access
to care and, consequently, reduce loss to follow-up during the pre-
ART period (Pilcher 2017; Rosen 2016). Lower loss to follow-up
may increase the absolute number of PLWH achieving viral sup-
pression (Pilcher 2017; Rosen 2016), reduce HIV transmission,
andHIV-relatedmorbidity, andmortality (Eshleman 2017; Lesko
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2016; Mfinanga 2015). The HIV continuum of care is however
a complex process, in which every cascade step is influenced by
multiple factors, as illustrated in our conceptual model (Figure 1).
The feasibility and acceptability of rapid ART initiation depends
on various health system and provider factors, such as: staffing
levels, skills, infrastructure and equipment, which vary across set-
tings (Attawell 2003); as well as: social; economic; cultural; and
individual drivers, including acceptance and motivation to take
ART (Black 2013; Black 2014; Katirayi 2016). Initiating treat-
ment before baseline screening test results are available could also
result in a higher frequency of adverse events which may result in
disengagement (Abay 2015; Chan 2016; Pilcher 2017), and reg-
imen modification (Pilcher 2017). It is essential that some these
negative influencing factors are limited for rapid ART initiation
to result in successful linkage and long-term retention in care.
Figure 1. Conceptual model of factors influencing the HIV care continuum
ART: antiretroviral therapy, IRIS: immune reconstitution inflammatory syndrome; PLWH: people living with
HIV
Why it is important to do this review
With universal ART being adopted worldwide, interventions
aimed at improving linkage to care - such as rapid ART - are
increasingly relevant. But, despite evidence that rapid ART im-
proves linkage and short term retention in care (Ford 2018; Rosen
2016), there remains uncertainty regarding long-term outcomes,
particularly for those who start ART on the same-day of diagno-
sis. In addition, evidence of improved uptake and retention has,
in part, been based on studies where the research context may
have substantially influenced outcomes (Geng 2017). Given these
concerns, we undertook a systematic review which rigorously ap-
praises and synthesizes evidence from RCTs of rapid ART and
characterizes the components of study interventions, in order to
further clarify the role of rapid ART initiation in HIV care.
O B J E C T I V E S
To assess the effects of rapid initiation of ART (defined as offering
ART within seven days of HIV diagnosis) on treatment outcomes
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and mortality in people living with HIV (PLWH). We also aim
to describe the characteristics of rapid ART interventions used in
the included studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs in which the unit of randomization was
either the individual or a cluster. We did not include non-ran-
domized studies as we anticipated there to be a significant evi-
dence base from randomized studies. Additionally, any effect seen
in non-randomized studies is likely to be confounded due to the
nature of the intervention.
Types of participants
Inclusion criteria
• Adults (aged 19 years or older), adolescents (aged 10 to 18
years), and children (aged 1 to 9 years) with a positive HIV test
(either a positive antibody test, a positive antigen test, or a
positive nucleic acid test), who were known not to have
previously received ART.
• Pregnant women who were receiving life-long ART for
their own health (Option B+ of the WHO system, see Table 1;
WHO 2012).
Exclusion criteria
• PLWH who receive ART in the context of pre-exposure
prophylaxis or post-exposure prophylaxis, or both.
• Infants (aged 0 to under 1 year).
• Pregnant women not receiving life-long ART for their own
health.
We excluded the last two groups (infants and pregnant women)
because they may have received ART as part of prevention of
mother to child transmission programmes, which did not include
life-long ART. For example, under WHO’s Options A and B-,
pregnant women with high CD4 cell counts and infants received
only a short course of antiretrovirals (WHO 2012).
Types of interventions
Experimental interventions
Any intervention that aims to initiate life-long ART within seven
days of HIV diagnosis. This may be combined with several other
services, including education, counselling, addressing social de-
terminants, clinical and laboratory assessments, or treatment of
comorbid conditions.
Comparator interventions
Comparison interventions offering the standard package of HIV
care. We included studies that used the same CD4/clinical stage
thresholds forART initiation in both intervention and comparison
groups.
Cointerventions
We included studies that offered rapid ART initiation within a
package of care alongside other interventions. These complex in-
terventions showed marked variation and we therefore describe
these narratively, including a comparative table (Table 2).
Types of outcome measures
Primary outcomes
• All-cause mortality rate.
• Virological suppression 12 months after a positive HIV test.
According to the WHO, viral suppression refers to “a viral load
below the detection threshold using viral assays” and defines viral
failure as the inability to achieve a viral threshold below 1000
copies/mL (WHO 2016). However, there is inconsistency in the
thresholds used in different settings and time periods to define
viral suppression (AIDSinfo 2015; EACS 2017; NASCOP 2016;
NDOHSA 2015). For this reason, we used the investigators’
study definitions of virological suppression or undetectable viral
load.
Secondary outcomes
• Retention in HIV care at 12 months after a positive HIV
test. We defined retention according to WHO guidelines, as
PLWH “who are enrolled in HIV care and routinely attend these
services in accordance to their needs” (WHO 2016). This
definition excludes those PLWH who either die or are lost to
follow-up. We considered the follow-up period to start at the
point of randomization to the intervention or comparator arm of
any study. There is a lack of consensus on the period of time that
a PLWH has to be disengaged with HIV services to be considered
lost to follow-up, usually ranging from three to six months after
the last attendance to services (Hønge 2013; Pilcher 2017). A
systematic review that analysed the sensitivity and specificity of
thresholds for loss to follow-up in 41 countries concluded that
the most appropriate definition would be failure to engage with
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services for more than 180 days after the last visit (Chi 2011).
Due to the variability and lack of a standard definition, we used
the investigators’ study definitions of loss to follow-up.
• Uptake of ART, defined as the proportion of eligible PLWH
offered ART who initiated the therapy.
• ART adherence, as documented by self-report, pill count,
pharmacy refills, or real-time electronic monitors such as
MEMScaps or Wisepill (Pellowski 2014), or a combination of
any or all of these.
• Incidence of treatment modification, defined as the number
and proportion of PLWH on ART who experience a regimen
modification in the intervention and control groups.
Adverse outcomes
We analysed the number and proportion of PLWH experiencing
adverse drug reactions associatedwithART in the intervention and
control groups and the number of HIV-negative people partnered
with aHIV-positive personwho became infectedwithHIV during
the study in each group. We also analysed the incidence of IRIS,
as defined by the study authors, and we included both paradoxical
and unmasking IRIS (AIDSinfo 2017).
Search methods for identification of studies
Electronic searches
Databases
We searched the following databases for relevant studies using
terms listed in Appendix 1;
• Central Register of Controlled Trials (CENTRAL 2018,
Issue 8) in the Cochrane Library (15 August 2018).
• Cochrane Database of Systematic Reviews (CDSR) (15
August 2018).
• MEDLINE (PubMed) (1966 to 15 August 2018).
• Embase Ovid (1947 to 15 August 2018).
• African Index Medicus (AIM) (1990 to 15 August 2018).
• Latin American and Caribbean Health Sciences Literature
(LILACS) (1982 to 15 August 2018).
• Web of Science-Core Collection (1970 to 15 August 2018).
We performed searches up to 15 August 2018. There was no re-
striction on date, language, or publication status.
International trials registries
We searched the following trials registries for unpublished or on-
going studies:
• ClinicalTrials.gov (www.clinicaltrials.gov) (15 August
2018).
• WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/) (15 August 2018).
Searching other resources
Grey literature
We searched the following sources of grey literature to identify any
relevant unpublished literature, including conference abstracts:
• International AIDS Society Online Resource Library (
library.iasociety.org/GlobalSearch.aspx).
• websites of the International AIDS Conference (IAS) on
HIV Science, International AIDS Conference, International
Conference on AIDS and STIs in Africa (ICASA), and the
Conference on Retroviruses and Opportunistic Infections
(CROI) for the years 2013, 2014, 2015, 2016, 2017, and 2018.
• the RAND publication database ( www.rand.org/
search.html).
Reference lists
We handsearched the reference lists of all included studies and
relevant systematic reviews to identify additional studies (for ex-
ample, unpublished or in-press citations).
Correspondence
We contacted study authors and subject experts for information
on unpublished or ongoing studies, or to request additional study
data where we considered necessary.
Data collection and analysis
Selection of studies
Wemerged studies identified by the keyword searches of different
databases and removed duplicate reports. Two review authors in-
dependently evaluated all the studies by reading the abstracts to
identify potentially relevant studies. We obtained full-text copies
of those articles that were potentially eligible and we decided on
whether the studies met the inclusion criteria with the aid of a
study eligibility form (see Appendix 2). We resolved all disagree-
ments by consulting a third review author. We listed all studies ex-
cluded after full-text assessment in the Characteristics of excluded
studies table.
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Data extraction and management
Two review authors independently extracted data from included
studies using a pre-piloted data collection tool. We resolved any
discrepancies by discussion, consulting a third review author when
necessary. Data points for extraction included the following:
• methods: study aim, design, unit of allocation, method of
allocation, and duration of study. For cluster-RCTs we extracted
the unit of analysis, the method of analysis, the average cluster
size, and the intraclass correlation coefficient (ICC);
• participants: setting, number, inclusion/exclusion criteria,
participant’s sociodemographic characteristics, method of
recruitment, withdrawals, and losses to follow-up;
• intervention and control: number of participants/clusters
randomized to intervention and control, description of
intervention and control, including time of ART initiation,
eligibility criteria, and complexity of intervention;
• outcomes: definition of outcome, method of measurement,
time points measured, person measuring, unit of measurement,
statistical power, and imputation of missing data;
• other: ethical approval, information consent, source of
funding, and possible conflicts of interests.
Assessment of risk of bias in included studies
Two review authors examined the components of each included
study for risk of bias using theCochrane ‘Risk of bias’ tool (Higgins
2017). This includes detailed information on sequence genera-
tion, allocation concealment, blinding (participants, personnel,
and outcome assessor), incomplete outcome data, selective out-
come reporting, and other sources of bias (Higgins 2017). For
cluster-RCTs included in the review, we also assessed the risk of
bias by including the five additional criteria specified in Section
16.3.2 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We assessed the methodological compo-
nents of the studies and have classified these as adequate (low risk
of bias), inadequate (high risk of bias), or unclear, as explained
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We also assessed and report the likely magnitude and direction of
biases and their likely impact on the findings. We resolved any
discrepancies by discussion or by consulting a third review author.
Measures of treatment effect
Dichotomous data
We reported outcome measures for dichotomous data (for exam-
ple, viral suppression yes/no) as risk ratios (RR) with 95% confi-
dence intervals (CIs).
Continuous data
Studies did not report continuous data for the outcomes of interest
in this review.
Timing of outcome assessment
For the outcomes of virological suppression and retention in care
at 12 months, we accepted the result closest to 12 months within
the range of 5 to 14 months. This is slightly different from the 6 to
14-month range specified in the protocol. SeeDifferences between
protocol and review for the rationale of extending the range.
For the secondary outcomes of incidence of treatment modifica-
tion and of number of people experiencing adverse drug events we
accepted the result closest to 12 months within a range of 6 to 14
months.
Unit of analysis issues
Cluster-RCTs
For cluster-RCTs, we used adjusted effect estimates and stan-
dard errors in our meta-analysis using the generic inverse-variance
method inReviewManager 5 (RevMan 5; Review Manager 2014).
When studies did not perform any adjustment for clustering, we
adjusted the raw data ourselves using the intraclass correlation
coefficient (ICC).
Repeated observations on participants
Some studies reported results from more than one time point.
In those cases we conducted separate analyses according to the
different outcomes defined (see Primary outcomes; Secondary
outcomes).
Studies with multiple treatment groups
One study (Elul 2017), included two different experimental arms
(combination intervention strategy (CIS) and CIS+ where par-
ticipants also received non-cash financial incentives) and a single
control arm. (See Characteristics of included studies.) In order
to avoid double counting in the meta analysis we included the
estimate of effect from the CIS versus control comparison only.
We were unable to split the control arm as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2017), as the study authors had adjusted for clustering using ran-
dom-intercept log-Poisson regression. We could have cluster-ad-
justed the data ourselves, however, this would have produced a less
precise estimate of effect. As there was no significant difference
between the CIS arm and the CIS+ arm for any of the outcomes
included in the review we decided to present the effect estimate
from the CIS arm versus control comparison only.
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Dealing with missing data
We attempted to contact the study authors to obtain missing data
when the lack of reporting of necessary data restricted the use of
the study.
We applied no imputation measures for missing data.
In order to analyse data as intention-to-treat we kept participants
in the group to which they had been randomized, regardless of
whether they had actually received the intervention (rapidART) or
not. Furthermore, to calculate primary and secondary outcomes,
we included in the denominator all randomized participants (
Higgins 2011).
Assessment of heterogeneity
We assessed the statistical heterogeneity in each meta-analysis by
inspecting forest plots and calculating Chi2 test values (Deeks
2017), and I2 statistics (Higgins 2003). We considered significant
heterogeneity to be present if the P value of the Chi2 test was
less than 0.10. We interpreted the I2 statistic according to the
thresholds recommended in the Cochrane Handbook of Systematic
Reviews of Interventions (Deeks 2017):
• 0% to 40%: low heterogeneity;
• 30% to 60%: moderate heterogeneity;
• 50% to 90%: substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We explored the causes of statistical heterogeneity by conduct-
ing a subgroup analysis (see Subgroup analysis and investigation
of heterogeneity). We also explored clinical and methodological
heterogeneity by assessing study populations, methods used, and
interventions delivered.
Assessment of reporting biases
We intended to use funnel plot analysis and statistical tests (such as
the Egger regression test) to assess for publication bias.We planned
to perform funnel plot analysis if there were more than 10 studies
in any meta-analysis. As there were fewer than 10 studies included
in any of the effects analyses, we did not perform an assessment
of reporting biases (Sterne 2017).
Data synthesis
We analysed data using RevMan 5 (Review Manager 2014). We
performed meta-analysis where appropriate, using a fixed-effect
model where we found no or low heterogeneity, according to
thresholds designated above. For outcomes where we found mod-
erate or substantial heterogeneity we used a random-effects model
in our analysis. We expressed the results of the primary outcomes
using forest plots. We also used forest plots to express the results of
the following secondary outcomes: retention in care at 12 months,
uptake of ART at 90 days and 12 months; and incidence of treat-
ment modification (Deeks 2017). Study authors did not report
data on the secondary outcomes of ART adherence and incidence
of IRIS. We, therefore, we did not include these outcomes in our
analysis. For cluster-RCTs, we used adjusted effect estimates if re-
ported. When adjusted effect estimates were not reported, we ad-
justed the raw data using the reported ICC (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We planned to carry out subgroup analyses by CD4 count (200
cells/µL or more, or fewer than 200 cells/µL), time to ART initia-
tion, age group, and geographical location, to investigate potential
sources of heterogeneity. We, however, did not find enough data
to carry out subgroup analysis by severity of HIV infection, as
only one study (Koenig 2017), stratified the results according to
our pre-specified CD4 count threshold (200 cells/µL).We did not
carry out a subgroup analysis by participants’ age group or by geo-
graphical location because none of the included studies recruited
children or adolescents, and because all the studies were carried
out in LMICs.
Althoughwe initially planned to only include studies where partic-
ipants randomized to the rapid ART group were offered the ther-
apy within seven days of diagnosis, we decided to include other
studies in which ART was expedited and where most participants
randomized to the intervention group were offered ART within
the first days after diagnosis, even if researchers did not use the
seven-day threshold to define the intervention. We clarified this
difference in the Differences between protocol and review section
and we carried out a subgroup analysis by time of ART initiation.
Four studies aimed to offer ART on the same day as diagnosis/
enrolment to the study, to PLWH randomized to the intervention
arm (Koenig 2017; Labhardt 2018; Rosen 2016; Stevens 2017).
One study aimed to offer ART to the intervention arm within
seven days of enrolment (McNairy 2017). Elul 2017 aimed to of-
fer ART within the first clinic visit in the intervention arm, which
was expedited. Amanyire 2016 aimed to offer ARTwithin 14 days
of enrolment to those in the rapid ART group. Also, during the
review process, we identified significant variation in study design.
As such, we conducted a subgroup analysis according to study de-
sign (cluster-designed RCTs versus individual RCTs).
Sensitivity analysis
We planned to conduct sensitivity analyses to investigate the effect
on the outcomes of:
• including and excluding studies we considered to be at high
risk of bias for random sequence generation according to
Cochrane’s ‘Risk of bias’ assessment;
• analysing the different assumptions made when imputing
missing data;
• analysing retention in care using different thresholds for
loss to follow-up.
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However, we did not find any study at high risk of bias for random
sequence generation. All the studies used similar assumptions to
input missing data. All studies used similar thresholds to define
retention in care.We therefore did not carry out any of the planned
sensitivity analyses.
‘Summary of findings’ table
We created a ‘Summary of findings’ table using GRADEpro soft-
ware (GRADEpro 2015), which displays the primary and sec-
ondary outcomes of the review (see Types of outcome measures),
the comparative risks between intervention and control groups,
the relative effects with 95% CIs, the number of participants in
the studies, and the certainty of the evidence. We classified the
certainty of the evidence for each of the outcomes as high, mod-
erate, low, or very low, according to an assessment using the five
criteria (limitations, inconsistency, indirectness, imprecision, and
publication bias) of the GRADE system (GRADE 2004).
R E S U L T S
Description of studies
Results of the search
We identified 10,001 references from two searches: an initial search
in February 2018 found 9313 references; and in August 2018 a
further 688 references were found. From these, after removing
duplicates, we identified 5367 unique references. We considered
5146 irrelevant to our review on initial screening. We considered
87 references for inclusion, of which we excluded 70, with reasons.
Seventeen references from eight unique studies met our inclusion
criteria and are included in the review. One of the studies was
only included in the qualitative synthesis; this is an ongoing study
where only preliminary results were available. We identified four
ongoing studies that may meet our inclusion criteria. The search
results and the reasons for exclusion are presented in a PRISMA
flow diagram (see Figure 2; Moher 2009).
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Figure 2. Study flow diagram
Included studies
See Characteristics of included studies, Table 2, and Table 3.
Study design
We included seven studies in our quantitative analysis. Three were
cluster-RCTs (Amanyire 2016; Elul 2017; McNairy 2017). Three
used individuals as the unit of randomization (Koenig 2017;Rosen
2016; Stevens 2017). One study used households as the unit of
randomization (Labhardt 2018). This study randomized house-
holds with more than one eligible individual to the same group
to reduce contamination. In total, they included 274 individuals
from 264 households. The study authors reported that, as there
were only 10 households including two participants, cluster-ad-
justment did not produce stable results and so they did not carry
out this procedure. In our review we agreed with the study authors
and analysed this study as an individual RCT.
Participants and setting
All the studies included participants aged 18 years or older. Only
one study included pregnant women (Stevens 2017). Female par-
ticipants constituted 48% to 66% of study populations and the
median CD4 count at ART initiation was above 200 cells/µL for
most but ranged from 165 to 417 cells/µL across study arms. CD4
threshold to determine eligibility of ART differed across studies.
In Elul 2017,McNairy 2017, Rosen 2016, and Stevens 2017, par-
ticipants were eligible for ART if their CD4 count was less than
350 cells/mm3. Amanyire 2016 and Koenig 2017 started with
the same threshold (350 cells/mm3) but, following changes in na-
tional guidelines, changed the ART eligibility criteria during the
study to include all participants with CD4 count fewer than 500
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cells/mm3. Labhardt 2018 was the only study to consider PLWH
eligible for ART irrespective of their CD4 count. All were con-
ducted in LMICs: two in South Africa; and one each in Lesotho,
eSwatini (formerly known as Swaziland), Uganda, Mozambique,
and Haiti. Two studies were conducted in urban settings (Koenig
2017; Rosen 2016), one in a rural setting (Labhardt 2018), three
in a mixture of rural and urban healthcare facilities (Amanyire
2016; Elul 2017;McNairy 2017), and one did not specify location
(Stevens 2017).
Interventions
Four studies aimed to start participants on ART on the same day
as diagnosis (Koenig 2017; Labhardt 2018; Rosen 2016; Stevens
2017). Elul 2017 offered ART on the first clinic visit; McNairy
2017 aimed to offer ART within seven days of diagnosis and
Amanyire 2016 within 14 days of diagnosis. We have summarized
the main characteristics of the included studies in Table 3.
Most studies conducted some assessment of ‘readiness to start
ART’ (Amanyire 2016;Koenig 2017; Labhardt 2018;Rosen 2016;
McNairy 2017). In Labhardt 2018, PLWH were asked if they
were ready to start ART. Amanyire 2016 changed the way they
carried out adherence counselling sessions to a more individual-
ized approach. Rosen 2016 assessed readiness to start ART during
counselling sessions. McNairy 2017 used a checklist, and Koenig
2017 assessed readiness through a survey administered by a social
worker.
Cointerventions
We found that rapid ART was frequently delivered alongside sev-
eral other interventions (Amanyire 2016; Elul 2017; Koenig 2017;
Labhardt 2018; McNairy 2017; Rosen 2016; Stevens 2017), tar-
geted at modifying individual or health workers’ behaviours, or
at modifying health system processes (Table 2). At the individ-
ual level, two studies included short message service (SMS) visit
reminders or noncash financial incentives, or both (Elul 2017;
Koenig 2017; McNairy 2017). Other studies expedited drug dis-
pensing at the pharmacy for those randomized to the rapid ART
arm (Rosen 2016), or included additional information highlight-
ing the importance of adherence to treatment (Labhardt 2018).
At the health-system level; the number of pre-ART counselling
sessions was reduced and they were frequently delivered on the
day of HIV diagnosis (Elul 2017; Koenig 2017; Labhardt 2018;
McNairy 2017; Rosen 2016; Stevens 2017). Five studies intro-
duced measures to obtain real-time point-of-care (POC) CD4 re-
sults in the rapid ART arm (Amanyire 2016; Elul 2017; McNairy
2017; Rosen 2016; Stevens 2017). One study also described expe-
diting tuberculosis (TB) screening before they offeredART (Rosen
2016). In Amanyire 2016, Rosen 2016, and Stevens 2017, health-
care workers received training on the new procedures and instru-
ments implemented (for example, POC instruments) before rapid
ART was delivered.
Table 2 summarizes cointerventions delivered alongside rapidART
in the included studies.
Outcomes
All seven studies reported on mortality and uptake of ART. Five
studies reported virological suppression at 12 months, with only
Elul 2017 and Stevens 2017 not reporting on this outcome. One
study, Amanyire 2016, reported mortality and viral suppression
for a randomly selected subset of study participants; these were
then inverse-probability weighted to represent the total study pop-
ulation and determine effect estimates.
All the included studies reported retention in care, using differ-
ent definitions to classify participants as lost to follow-up and to
measure retention in care. Elul 2017 and McNairy 2017 classified
participants as retained in care if they attended a clinic visit within
the 90 days prior to the end of the study (12 months after ran-
domization). Koenig 2017 defined retention in care as attending
the 12-month visit (1 clinic visit between 12 and 15 months after
HIV testing). Rosen 2016 classified participants as retained in care
if they attended a clinic visit within 5 to 10 months after study en-
rolment. Labhardt 2018 classified participants as retained in care
if either they or a treatment “buddy” attended a health facility
to get a drug refill between 11 and 14 months after enrolment.
Stevens 2017 defined retention in care as participants not missing
an appointment by over 60 days; and reported the results at 6 and
12 months. We used the 12-month data in our analysis because
it was closer to the other studies’ measuring time. We could not
use data from Amanyire 2016 in the retention analysis as they
measured the mean number of visits per 90 days in each group.
We found two studies that reported on treatment modification
(Koenig 2017; Labhardt 2018).
Excluded studies
See Characteristics of excluded studies.
We excluded several studies as they assessed the effect of ART
initiation related to CD4 threshold rather than initiating ART
soon after HIV diagnosis (Achhra 2017; Danel 2015; Iwuji 2017;
Sabapathy 2017; Larmarange 2016; Plazy 2016; Temprano 2015).
We further excluded studies that specifically assessed timing of
ART in participants who had oppurtunistic infections such as
cryptococcal meningitis or tuberculosis meningitis (Bisson 2013;
Blanc 2011; Boulware 2014; Degu 2012; Grant 2010; Havlir
2011; Laurelliard 2013; Makadzange 2010). We considered that
these studies focused on population subgroups, whose clinical
management and guidelines differ from those of the general pop-
ulation of PLWH (WHO 2018).
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Studies awaiting classification
We did not identify any studies awaiting classification.
Ongoing studies
We identified
three ongoing studies (Rosen 2017; PACTR201706002322546a;
Sikazwe 2018). For more details about ongoing studies see the
Characteristics of ongoing studies section.
Risk of bias in included studies
See Figure 3 and Figure 4 for a summary of the ‘Risk of bias’ as-
sessments. We have presented further details in the Characteristics
of included studies section.
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
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Figure 4. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Allocation
Sequence generation
Six studies described the use of random methods in the sequence
generation process, so we judged them to be at low risk of bias for
this domain. One study, Rosen 2016, did not explain in detail the
methods used to create the sequence generation. For this reason
we judged this study to be at unclear risk of selection bias.
Allocation concealment
Six studies described the use of appropriate allocation conceal-
ment methods, such as opaque envelopes, which prevented par-
ticipants and investigators from foreseeing the allocation group of
participants, so we judged them to be at low risk of selection bias.
One study, Stevens 2017, did not describe allocation concealment
methods; we therefore judged it as unclear risk of bias in this do-
main.
Blinding
Performance bias
We judged all seven studies to be at high risk of performance bias.
All studies were open-label studies and could not mask partici-
pants or personnel. Whilst we acknowledge that the nature of the
intervention made blinding impossible, we judged that lack of
blinding could affect the performance of participants. Participants
could be more likely to be retained in care and be initiated on
ART if they were aware that they were part of the experimental
arm of a study. Personnel could also be more likely to encourage
participants to remain in care or to initiate ART, or both, if they
were aware of which participants were in the intervention group.
This could have an effect not only on the outcomes of retention
in care and ART uptake, but also on the primary outcomes, as
individuals who initiate ART and are retained in care are more
likely to be virologically suppressed.
Detection bias
Three studies collected data on the outcomes through retrospective
medical records (Elul 2017; McNairy 2017; Rosen 2016). Three
studies gave no information about blinding of outcome assessors
(Amanyire 2016; Labhardt 2018; Stevens 2017), and one study
reported that statisticians were not blinded (Koenig 2017).
We judged all studies to be at low risk of detection bias, as the out-
comes measured were objective and did not rely on interpretation
or on self-reported measures.
Incomplete outcome data
We judged separately attrition bias for the outcome of mortality
because we considered that ascertaining this outcome in PLWH
lost to follow-up was more problematic than for the outcomes of
virological suppression, retention in care, or uptake of ART; as we
deemed reasonable to consider those lost to follow-up as not being
virologically suppressed, initiated ART or retained in care, as most
authors did. We judged four studies to be at high risk of attrition
bias for the outcome of mortality because attrition rates were high
and significantly different between the intervention and the con-
trol groups (Amanyire 2016; Elul 2017; McNairy 2017; Rosen
2016). They ranged from 19% to 42% in the intervention group
and from 21% to 56% in the control group. We judged Koenig
2017 and Labhardt 2018 to be at low risk of attrition bias for the
outcome of mortality because attrition rates were below 25% in
both groups. Stevens 2017 had high rates of attrition in both arms.
We judged it to be at low risk of bias for the outcome of mortality
because they undertook additional efforts to ascertain vital status.
The mortality rate found was in-line with that described in other
cohorts.
We did not consider that high attrition rates would bias the esti-
mate effect of virological suppression, as we judged it appropriate
to assume that PLWH lost to follow-up would not be virologi-
cally suppressed. We judged that attrition would not affect the
outcomes of retention in care and uptake of ART for the same
reason. So, we judged all studies to be at low risk of attrition bias
for these outcomes.
Selective reporting
We judged all the studies to be at low risk of reporting bias. Six
studies prespecified the outcomes measured in published proto-
cols. We did not find prespecified outcomes for Stevens 2017, but
they reported all relevant and non-significant outcomes.
Other potential sources of bias
We judged two studies to be at high risk of bias in the selection of
participants because these studies enrolled only those participants
who were ready to commence ART (Koenig 2017; Rosen 2016).
This could potentially bias the estimates of effect for the outcomes
of uptake and retention in care by introducing bias in the selection
of participants. The other studies did not exclude participants on
the basis of being ready to start ART (Amanyire 2016; Elul 2017;
Labhardt 2018; McNairy 2017; Stevens 2017).
Risk of bias in cluster-RCTs
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We assessed five additional risks of bias in the three cluster-RCTs,
as recommended by the Cochrane Handbook of Systematic Reviews
of Interventions (Higgins 2011): recruitment bias, baseline com-
parison concerns, missing clusters, correct statistical analysis, and
contamination.
Recruitment bias
We judged all three studies to be at high risk of recruitment bias
(Amanyire 2016; Elul 2017; McNairy 2017). Participants were
aware of the clinics allocated to the intervention group, which
could have made them more likely to seek care at these clinics due
to the perception of receiving higher quality of care.
Baseline comparison concerns
We found no baseline imbalances in two studies (Elul 2017;
McNairy 2017). One study had significant imbalances between
the intervention and control group at baseline and we judged it to
be at high risk of bias for this domain (Amanyire 2016).
Loss of clusters
None of the trials lost any cluster to follow-up and they included
all randomised clusters in the analysis, so we judged all studies to
be at low risk of bias for this domain
Statistical analysis
All studies described appropriate statistical methods of adjusting
for clustering and we judged them to be at low risk of bias in this
domain.
Contamination
Given the nature of the intervention and the outcomes analysed,
we considered that a “herd effect” leading to contamination was
unlikely and, therefore, we judged them to be at low risk for this
domain.
Effects of interventions
See: Summary of findings for the main comparison Rapid
antiretroviral therapy (ART) compared to standard care for people
living with HIV
We have presented main effects and subgroup analyses. Subgroup
analyses should be interpreted with caution due to the limited
number of studies contributing to subgroups for all analyses.
We have also presented main effects and GRADE assessments in
Summary of findings for the main comparison
Primary outcomes
Mortality
There was some evidence that rapid initiation of ART in people
newly diagnosed with HIV reduced the risk of dying. However,
this effect was not seen at the 95% confidence level (RR 0.72,
95% CI 0.51 to 1.01; 5451 participants, 7 studies; I2 = 0%; very
low-certainty evidence; Analysis 1.1; Figure 5).
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Figure 5. Forest plot of comparison 1. Rapid ART versus standard care, outcome 1.1, mortality
Subgroup analysis by timing of ART initiation (Analysis 2.1),
showed no difference in the risk of dying if ART was initiated on
the same day as diagnosis (RR 0.59, 95% CI 0.34 to 1.02, 1786
participants, 4 studies, I2 = 0%), within seven days (RR 0.80, 95%
CI 0.46 to 1.39; 2197 participants, 1 study), at the first clinic visit
(RR 0.87 95% CI 0.40 to 1.89; 1031 participants, 1 study) or
within 14 days after diagnosis (RR 0.65, 95% CI 0.14 to 3.02;
437 participants, 1 study).
Virological suppression
Those who initiated ART rapidly were more likely to be virally
suppressed at 12 months (RR 1.18, 95% CI 1.10 to 1.27; 2719
participants, 4 studies, I2 = 13%; moderate-certainty evidence;
Analysis 1.2; Figure 6).
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Figure 6. Forest plot of comparison 1. Rapid ART versus standard care, outcome 1.2, virological
suppression at 12 months
There was variation in how the studies measured viral suppres-
sion. All the studies, apart from McNairy 2017 measured viro-
logical suppression in all randomized participants; McNairy 2017
assessed virological suppression only for those who had been on
ART at least for six months. It was not possible to obtain the de-
nominator of all ART-eligible participants, so we excluded this
study from the analysis of this outcome. McNairy 2017 found no
differences between the rapid ART group and the control group
when measuring virological suppression in those on ART for at
least six months (RR 0.98, 95% CI 0.93 to 1.02; Analysis 3.1).
Subgroup analysis by timing of ART initiation revealed no dif-
ference between same-day (RR 1.24, 95% CI 1.12 to 1.37; 1354
participants, 3 studies; I2 = 0%) and 14-day ART initiation (RR
1.13, 95% CI 1.02 to 1.25; 437 participants, 1 study; Analysis
2.2).
Secondary outcomes
Retention in care
Four RCTs (Koenig 2017; Labhardt 2018; Rosen 2016; Stevens
2017), and two cluster-RCTs (Elul 2017; McNairy 2017), mea-
sured retention in care at 12 months. Those randomized to rapid
ART were 22% more likely to be retained in care at 12 months
(RR 1.22, 95% CI 1.11 to 1.35; 5001 participants, 6 studies; I2 =
54%; low-certainty evidence; Analysis 1.3). There was moderate
heterogeneity (I2 = 54%), which may have been caused by the
different methods used to define retention in care across studies.
The subgroup analysis by timing of ART initiation showed some
difference between groups (Analysis 2.3; test for subgroup differ-
ences P = 0.05; I2 = 66.8%). However, all subgroups showed better
retention in the intervention arm.
Amanyire 2016 measured retention in care by calculating visit
adherence as the mean number of visits per participant and the
proportion of scheduled visits attended. They did not find any
differences between the intervention and control groups (RR 1.00,
95% CI 0.99 to 1.01).
Uptake of ART at 90 days
Three RCTs (Koenig 2017; Labhardt 2018; Rosen 2016), and one
cluster-RCT (Amanyire 2016),measured uptake at 90 days. Those
randomized to rapid ART were more likely to start ART within
90 days of enrolment (RR 1.31, 95% CI 1.18 to 1.45; 11,404
participants, 4 studies, I2 = 94%; low-certainty evidence; Analysis
1.4).
We investigated possible sources of clinical and methodological
heterogeneity. We subgrouped by timing of ART initiation (same
day versus 14 days from diagnosis), but could not explain the
observed heterogeneity (Analysis 2.4).
Uptake of ART at 12 months
Those randomized to rapid ART were more likely to have started
ARTat 12months comparedwith those who received the standard
care (RR 1.09, 95% CI 1.06 to 1.12; 3713 participants, 4 studies;
I2 = 32%; moderate-certainty evidence; Analysis 1.5).
There were no differences in the subgroup analysis between those
initiating ART on the same day as diagnosis, within seven days of
diagnosis or at the first clinic visit (Analysis 2.5).
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Treatment modification
We found that those randomized to rapid ARTweremore likely to
experience treatment modification compared with those random-
ized to the standard care arm (RR 7.89, 95% CI 0.76 to 81.74;
977 participants, 2 studies; I2 = 41%; very low-certainty evidence;
Analysis 1.6).
Adverse events
One study reported adverse events (Labhardt 2018). Six partici-
pants out of 137 in the rapid ART group reported adverse events
(2 experienced rash, 1 dizziness, 1 gynaecomastia, and 1 had el-
evated alanine aminotransferase levels). Two participants experi-
enced adverse events (rash) in the standard care arm.
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
We included seven studies in this review: six were carried out in
sub-Saharan Africa, and one study was conducted in Haiti. Four
were individually RCTs with a total of 1786 participants and three
were cluster-RCTs with 16,225 participants. The study popula-
tion included adults aged 18 years and older from urban and rural
areas. Four studies offered participants ART on the same day as
diagnosis, one within seven days, another within 14 days, and an-
other at the first clinic visit. There was substantial heterogeneity of
intervention delivery methods and cointerventions. Most studies
initiated ART at the health facility and one provided home-based
ART initiation. Three studies distributed non-cash financial in-
centives, two studies usedmobile phone visit reminders, one study
reported opinion-leader training of health staff, several provided
point-of-care CD4 testing, one provided multi-month ART pre-
scriptions, and there were variable approaches to assessing partic-
ipant ‘readiness’ to start ART.
Primary outcomes
Although there was some evidence of reducedmortality with rapid
ART, high levels of attrition, indirectness, qualitative heterogene-
ity, and imprecision resulted in very low-certainty in the pooled
effect estimate for this outcome. Subgrouping by study design or
time to ART initiation also did not show any significant effect of
rapid ART in any of these groups. Rapid ART probably improves
virological suppression at 12 months. There was moderate-cer-
tainty evidence contributing to this outcome; the beneficial effect
on virological suppression was seen across subgroups with variable
time to ART initiation.
Secondary outcomes
RapidARTprobably improves uptake of ART at 12months (mod-
erate-certainty evidence), and this effect was seen across subgroups
for study design and time to ART initiation. Rapid ARTmay also
improve uptake of ART at 90 days and improve retention at 12
months, with low-certainty evidence contributing to these out-
comes. Finally, we do not know if those receiving ART are more
likely to experience treatment modification.
Adverse events/harms
There was insufficient evidence regarding adverse events to draw
conclusions for this outcome.
Overall completeness and applicability of
evidence
The included studies were conducted in adults in LMICs and
therefore are only generalizable to these groups. Numerous coint-
erventions were also included in the delivery of rapid ART, high-
lighting that in order to achieve these study outcomes, several ad-
ditional changes need to be made to health system structures and
processes. Healthcare staff need to be trained to accelerate clini-
cal and psychological assessments, and incentives as well as gen-
eral improvements in treatment support and health worker ap-
proach may be required. Given the differences in cointerventions
and how delivery modes varied across studies, the direct applica-
bility of these results to other settings may be limited. All stud-
ies, however, demonstrated benefit, suggesting that setting-specific
delivery methods, which are combined with appropriate cointer-
ventions that enhance services and seek to reduce barriers to care
are likely to result in comparable results during implementation
in other settings. No studies presented long-term outcomes; we
therefore cannot make inferences regarding long-term treatment
outcomes based on these data. Finally, ART eligibility criteria dif-
fered across studies and only one study considered PLWH eligible
for ART irrespective of CD4 count, which is the current WHO
recommendation. It is possible that rapid ART’s effectiveness dif-
fers in PLWH according to severity of disease, which we have not
been able to analyse in this review.
Certainty of the evidence
We foundmethodological limitations for several outcomes that re-
sulted in downgrading the certainty of the evidence for risk of bias.
High levels of attrition across studies (ranging from 17% to 42%)
could have affected mortality outcome assessments; this however
was not a concern for other outcomes such as uptake, virological
suppression and retention in care. All the studies were unblinded
resulting in a high risk of performance bias for participants and
personnel, specifically for ART uptake and retention in care at 12
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months. We further downgraded the mortality, virological sup-
pression, and retention in care outcomes for indirectness, as two
studies (Elul 2017; McNairy 2017), included ART-ineligible par-
ticipants in their denominators, and several cointerventions were
delivered alongside rapid ART, which could impact the outcomes
measured.We further downgraded for qualitative heterogeneity, as
there was variation in time to ART initiation, which ranged from
same-day start to initiation at 14 days after diagnosis. Marked sta-
tistical heterogeneity of the 90-day ART uptake outcome, which
could not be explained by subgrouping, led to downgrading of
this outcome. Finally, imprecision due to few events or wide CIs of
pooled effect estimates, or both, led to downgrading of mortality,
90-day ART uptake and treatment modification outcomes.
Potential biases in the review process
We minimized bias in the review process by conducting an ex-
tensive search using a wide range of search terms and databases.
Two review authors independently assessed the search results to
evaluate which articles were eligible for our review. By limiting
our analysis to RCTs we have minimized the risk of bias derived
from non-randomized study designs. We further minimized the
risk of bias in cluster-RCTs by reporting the cluster-adjusted es-
timates of effect when available and using appropriate methods
for cluster-adjustment. Lack of data (only one study reported on
adverse events) limited our ability to comment on the potential
harms associated with rapid ART.We could not assess publication
bias due to the limited number of studies included in the review.
Agreements and disagreements with other
studies or reviews
Our synthesis supports findings from an earlier systematic review
andmeta-analysis conducted by Ford 2018, which similarly found
that rapid ART improved uptake, virological suppression, and re-
tention in care at 12 months. We have included an additional four
studies (Elul 2017;McNairy 2017; Labhardt 2018; Stevens 2017),
and have found similar or stronger associations for primary and
secondary outcomes.
Findings from observational studies support results from this re-
view and demonstrate better or similar outcomes between early
and delayed ART (Table 4). Data from general adult population
cohort studies have shown better uptake and time to viral suppres-
sion among those initiating ART early compared to more delayed
ART initiation, and no difference in retention in care in the one
cohort reporting on this outcome (Pilcher 2017). Oladele 2018
evaluated different rapid ART delivery methods and determined
that community-based rapid ART was more effective than refer-
ral for facility-based rapid ART. Among pregnant women, same-
day ART initiation appeared to result in similar retention or viral
suppression compared to delayed treatment (median seven days;
Langwenya 2018). Vogt 2017 evaluated ART initiation within
seven days compared to beyond seven days in children and showed
better retention and survival among early ART initiators, although
numbers were small. An additional cohort study conducted in
adolescents showed no significant difference on retention or mor-
tality among those who initiated ART early compared to those
with more delayed ART start (Ssebunya 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, interventions that include rapid initiation of antiretrovi-
ral therapy (ART) appear to improve outcomes across the HIV
treatment cascade, at least in the short term. Those implementing
this intervention should consider the cointerventions and health
system modifications required to facilitate rapid delivery of ART
and ensure effectiveness.
Implications for research
Now that rapid ART is being implemented widely, researchers
need to consider what the best modes of implementation are,
how to adapt health systems and what cointerventions to offer
within resource constraints in order to support patients to accept
ART, and link to care and remain engaged in care in the long
term. Pragmatic research that helps define ‘treatment readiness’,
explores cointerventions that are feasible, and defines treatment
delivery modes within complex health system interventions will
help specify how to implement rapid ART.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amanyire 2016
Methods Stepped-wedge, cluster-RCT in a network of 20 health facilities in Uganda
Participants 15,000 treatment-naïve participants were drawn from healthcare clinics in urban and
rural areas
Inclusion
• All HIV-infected adults (aged ≥ 18 years).
• Clinically eligible for ART (by clinical or CD4 cell count criteria) during the
study period.
Interventions Intervention group
• Opinion-leader-led training and coaching of front-line health workers.
• POC CD4 cell count testing platform.
• A revised counselling approach without mandatory multiple pre-initiation
sessions.
• Feedback to the facilities on their ART initiation rates and how they compared
with other facilities.
Control group
• Standard care.
Outcomes ART initiation within 14, 30 and 90 days after the first date of clinical eligibility for
ART, HIV RNA suppression and survival 1 year after ART eligibility; retention in care;
vertical transmission; cost and cost-effectiveness
Notes HIVRNA suppression and survival 1 year after ART eligibility were assessed in a random
subsample of 437 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was stratified by
four facility levels defined by size and time
offering HIV care and treatment services.
Randomisation was done with a random
number generator in Stata (version 13).
Random allocation of clinics was done by a
statistician who was not otherwise involved
with the study planning or analysis”
Allocation concealment (selection bias) Low risk Authorsmention that random allocation of
clinics was carried out by a statistician who
was otherwise not involved in the study
planning or analysis
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Amanyire 2016 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was a non-blinded study. The fact that
participants and researchers knew the allo-
cation group of participants could have af-
fected the primary outcome (ART initia-
tion) and subsequently the other secondary
outcomes (virological suppression and re-
tention in care)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk There is no information around outcome
assessment. However, due to the objective
nature of the outcomes (ART initiation, re-
tention and virological suppression), it is
unlikely that these would be influenced by
the unblinded nature of the study
Incomplete outcome data (attrition bias) Low risk There were almost 3000 participants ran-
domized who were excluded because they
were not eligible for ART. The rest of the
randomized participants had the primary
outcome assessed. Study authors selected a
subsample of 437 to follow up after a year
and theywere able to measure outcomes on
75% in the intervention group and 79%
in the control group. It is unlikely that at-
trition could bias the estimate effect of the
outcomes of retention in care, uptake of
ART and virological suppression
Incomplete outcome data (attrition bias)
Mortality
High risk Study authors were unable to measure the
outcome of mortality on 25% of the in-
tervention group and 21% of the control
group. These high rates could have biased
the estimate effect of mortality
Selective reporting (reporting bias) Low risk The outcomes were prespecified in the pro-
tocol. They were changed to make them
more specific, but they were altered before
the data were collected
Other bias Low risk We did not identify any other risks of bias.
Recruitment bias High risk The fact that participants knew which clin-
ics were allocated to the intervention along-
side the prospect of receiving a higher-qual-
ity of care could have made certain groups
choose an intervention clinic over a control
one
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Amanyire 2016 (Continued)
Baseline comparison concerns High risk There were significant imbalances between
the intervention and control arms at base-
line. For example, the number of partic-
ipants eligible for ART was significantly
higher in the control arm (61%) compared
with the intervention arm (39%)
Correct statistical analysis Low risk Study authors took clustering into account
and adjusted the results using appropriate
statistical methods
Loss of clusters Low risk All clinics randomised were included in the
final analysis
Contamination Low risk We considered that there is nopossible herd
effect that could make those PLWH who
are closer to intervention clinics less likely
to develop the outcomes
Elul 2017
Methods Non-blinded, cluster-RCT. 10 clinics in Mozambique were randomized to either inter-
vention (CIS) or control (standard care). A pre-post intervention 2-sample design was
nested within the intervention arm to assess the additional effectiveness of an enhanced
version of the CIS, referred to as CIS+. Consequently, the standard care arm enrolled 1
cohort of patients, while the intervention arm enrolled 2 sequential cohorts of patients
(CIS and CIS+). CIS+ participants were enrolled after CIS enrolment was completed at
each facility randomized to the intervention arm
Participants 5327 participants
5 clinics were selected from urban areas and 5 from rural areas
Inclusion
• All adults testing HIV-positive in the VCT clinics within the participating health
facilities
Exclusion
• < 18 years of age.
• Pregnant.
• Planned to move from their community of residence in the next 12 months.
• Had enrolled in HIV care or initiated ART in the past 6 months.
• Did not understand Portuguese or Xitsua.
• Were incapable of providing informed consent.
Interventions Intervention arm: 4 evidence-based interventions that simplified the clinic flow and
encouraged linkage to and retention in care:
• Pima (Inverness Medical Innovations) CD4 assay machines in the VCT clinics to
enable HIV testing counsellors to provide real-time, POC CD4 test results
immediately following diagnosis.
• Participants with Pima CD4 cell count < 350 cells/mm3 were provided with rapid
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Elul 2017 (Continued)
ART initiation. These individuals received an individual ART preparatory counselling
session in the VCT clinic immediately following CD4 testing, on the day of diagnosis.
Facility receptionists were instructed to expedite appointments for these participants
when they presented to schedule their clinical consultations. Clinicians were
encouraged to initiate ART at the first clinical visit.
• Participants received health messages and appointment reminders via SMS
messaging.
• participants in the CIS+ cohort received the CIS interventions plus a series of
non-cash FIs in the form of prepaid cellular air-time cards.
Control: standard care - participants were managed as per prevailing Ministry of Health
guidelines
• Individuals diagnosed with HIV received post-test counselling in the VCT clinic
and were referred verbally to HIV services.
• Participants presenting to the facility receptionist to schedule a clinical
consultation for HIV care were referred to the laboratory for CD4 cell count,
chemistry, and haematology testing, and provided with an appointment 2-4 weeks later
to allow sufficient time for the laboratory results to be received.
• ART eligibility was determined at that first clinical consultation based on CD4
cell count < 350 cells/mm3 and/or WHO stage 3/4.
• Those found to be eligible for ART received at least 1 individual counselling
session before initiating treatment.
• For ART-eligible participants, the time interval between enrolment in HIV care
and ART initiation was estimated at 1-2 months at the time the study started.
• Participants initiating ART were requested to return every 2 weeks for the first
month, at 2 months, at 6 months, and every 6 months thereafter.
• ART-ineligible participants were instructed to return at 6 months for repeat
clinical evaluation and laboratory testing.
Outcomes Mortality and viral suppression at 12 months, time to ART initiation, linkage to care at
1 month, retention in care at 6 months, disease progression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Matched pairs were randomised
by one of the authors (MRL) using a com-
puterized random number generator to ei-
ther the CIS arm or the standard care arm
using matched-pair randomization.”
Allocation concealment (selection bias) Low risk Quote: “Sequenceswere concealed until in-
terventions were assigned.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was non-blinded. The fact that
participants knew that they were taking
part in an experimental study could affect
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Elul 2017 (Continued)
their performance in relation to primary
outcomes (linkage and retention in care) as
well as some of the secondary outcomes (for
example, ART initiation)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed through the electronic
medical records of participants are at low
risk of detection bias
Incomplete outcome data (attrition bias) Low risk Although LTFU rates were high (42% and
56% in the intervention and control group)
, attrition is unlikely to affect the outcomes
of retention in care, uptake of ART and
virological suppression
Incomplete outcome data (attrition bias)
Mortality
High risk The high LTFU rates and the significant
differences between the intervention and
control group means that attrition could
bias the estimate of effect of mortality
Selective reporting (reporting bias) Low risk Study outcomes have been described in the
published protocol
Other bias Low risk We did not identify any other risks of bias.
Recruitment bias High risk Clinics were matched by various character-
istics, including setting (urban and rural)
. There isn’t enough information to know
where exactly the clinics were situated. But
there is a possibility that PLWH decided
to attend a clinic with the intervention be-
cause they knew of the package of care that
was offered
Recruitment continued after randomiza-
tion, potentially affecting the recruitment.
However baseline characteristics between
intervention and comparator arm are sim-
ilar
Baseline comparison concerns Low risk There were no significant imbalances be-
tween groups at baseline assessment
Correct statistical analysis Low risk The study authors took clustering into ac-
count and adjusted the results using appro-
priate statistical methods
Loss of clusters Low risk All clinics randomised were included in the
final analysis
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Elul 2017 (Continued)
Contamination Low risk There is no possible herd effect that could
make those PLWH who are closer to in-
tervention clinics less likely to develop the
outcomes
Koenig 2017
Methods Open-label RCT in Haiti
Participants 762 participants
Inclusion
• Age ≥18 years.
• Ability and willingness of participant to give written informed consent.
• CD4 cell count ≤ 500 cells/mm3.
• WHO stage 1 or 2 disease.
Exclusion
• Any use of ART in the past.
• Pregnancy or breastfeeding at the screening visit.
• Psychologically unprepared to start ART, based on ART readiness survey.
• Plans to transfer care to another clinic during the study period.
• WHO stage 3 or 4 disease.
Interventions Intervention
• Day of presentation: HIV testing, CD4 count, physician evaluation, first
adherence counselling visit with social worker; physician visit for ART initiation and
ART initiation.
• Days 3, 10 and 17: first, second and third adherence counselling visits with social
worker; physician visit to assess for opportunistic infections and provide adherence
counselling.
• Day 24 and Week 7: physician visits for medical assessment and adherence
counselling.
• Participants also had prophylactic treatment with trimethoprim-
sulphamethoxazole and isoniazid. Field workers phoned participants who missed a visit
and attempted a home visit for those not reachable by phone.
Control
• Days 7, 14: first and second adherence counselling visits with social worker;
physician visit to assess for opportunistic infections and provide adherence counselling.
• Day 21: third adherence counselling visit with social worker; physician visit for
ART initiation.
• Week 5: fourth adherence counselling visit with social worker; physician visit to
assess for opportunistic infections and provide adherence counselling.
• Week 7: physician visit for medical assessment and adherence counselling.
Outcomes Retention in care at 12 months, viral suppression at 12 months, adherence to ART,
uptake of ART, cost-effectiveness of standard and same-day ART initiation
Notes
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Koenig 2017 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomly assigned with the use
of a computer-generated random-number list to either stan-
dard ART or same-day ART initiation in a 1:1 ratio, with
allocation concealment. The randomization sequence was
generated by a computer in the GHESKIO data manage-
ment unit by a datamanager who had no other involvement
in study procedures”
Allocation concealment (selection bias) Low risk Authorsmention that “Participants were randomly assigned
with the use of a computer-generated random-number list
to either standard ART or same-day ART initiation in a 1:
1 ratio, with allocation concealment”.
However, there is not description of the method used for
allocation concealment, and therefore it is not possible to
assess in detail how valid it was
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label study.
Quote: “Participants, site personnel, and study statisticians
were not masked to group assignment.”
The main outcome was retention in care with viral suppres-
sion. LTFU was defined as “failure to attend the 12-month
visit.” If participants knew that they were allocated to the
experimental arm of a new trial, they may have been more
likely to attend the follow-up visit
The same argument is valid for the secondary outcomes of
uptake and adherence
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes were defined objectively and did not rely on sub-
jective reports. So, the fact that assessors knew the alloca-
tion group of participants is unlikely to have affected the
assessment
Incomplete outcome data (attrition bias) Low risk Study authors used a “modified intention-to-treat approach.
.., in which all patients were analysed according to their
assignment group, excluding patients who transferred to
another facility during the follow-up period, according to
protocol.”
The number of participants excluded due to transfer to
another facility was 28/384 in the control group and 31/
378 in the intervention group
The number of participants LTFU in the intervention group
was 17% and in the control group 23%
Given that a similar number of participants across groups
were excluded for the same reason and that “Plans to transfer
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to another clinic” was an exclusion criteria pre-defined in
the protocol, the risk of attrition bias is low
Incomplete outcome data (attrition bias)
Mortality
Low risk Quote: “Vital status at the end of the study was known for
328 (92%) participants in the standard ART group and 329
(95%) in the same-day ART group.”
Therefore, the risk of attrition bias is low.
Selective reporting (reporting bias) Low risk The primary outcomes pre-specified in the protocol were
reported
Study authors added a number of outcomes that were not
in the original protocol
• retention with undetectable viral load at < 200
copies/mL and < 1000 copies/mL cut-off points. Only
reported at < 1000 copies/mL and not at < 200 copies/mL
• proportion of participants who initiate ART during
the study period.
However, it is highly unlikely that the outcome < 200
copies/mL would give any additional or relevant informa-
tion not captured by the other thresholds reported
Other bias High risk Selection bias: quote, “Patients were excluded if failed to
demonstrate preparedness on an ART readiness survey,
which was administered by a social worker prior to study
enrolment. The survey includes a 5-point scale, with re-
spondents ranking their preparedness from “not at all ready”
to “completely ready” in response to 7 questions. Study in-
clusion required a response of “somewhat ready” or “com-
pletely ready” for all 7 questions”
Labhardt 2018
Methods Multicenter, 2-group, open-label RCT in Lesotho
Participants 278 participants randomized from 268 households
Inclusion
• HIV infection newly diagnosed during community-based HIV testing and
counselling (HTC)-campaign.
• Never been on triple-ART.
• Lived and/or worked in the district of Butha-Buthe and declared to seek follow-
up at one of the 6 health facilities involved in the study.
• Signed written informed consent.
Exclusion
• Pregnant or breast-feeding.
• Already enrolled in chronic care for another disease, such as TB or diabetes.
• Clinical WHO-stage 4 or active tuberculosis.
• Positive cryptococcal antigen test.
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Interventions Intervention arm: In the same-day group
• Participants were offered same day ART initiation.
• Participants received pre-ART counselling directly after testing, accompanied by a
leaflet that summarized the key points of ART adherence.
• If they agreed to start therapy within the upcoming days, the study nurse left a
30-day supply of ART.
• Once participants linked to care at the health facility and had their first health
facility visit (including ART dispensing), they followed the usual care for ART patients
with the exception of longer intervals between follow-up visits (1.5, 3, 6, 9, and 12
months after ART start).
Control arm: participants randomized to the usual care group followed the usual care
provided in Lesotho, which is similar to most settings in southern Africa
• They received post-test counselling in the home and an appointment at their
nearest health facility within the next 28 days.
• Once linked to care, they had to undergo at least 2 pre-ART health facility visits.
• During the first health facility visit, blood was drawn for baseline laboratory work
and a first pre-ART counselling session was conducted.
• At the second health facility visit, laboratory results were communicated and the
participant’s readiness to start ART was assessed.
• Depending on the judgment of the health facility staff, the participant was offered
to start ART.
• Once ART was started, the participants were given monthly follow-up and drug
refill dates.
Outcomes Mortality, virological suppression and retention in care at 12 months, uptake of ART
and number of visits attended
Notes Study authors effectively randomized households, as they mention that households with
> 1 eligible individual were automatically allocated to the same group to reduce con-
tamination between the groups. However, we treated it as an individual RCT as only 10
households (5 in each arm) had 2 participants)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated randomiza-
tion list was generated in block sizes of 4.”
Allocation concealment (selection bias) Low risk Quote: “A separate person, not involved in
the trial, prepared the sealed, sequentially
numbered, opaque envelopes. The study
nurse allocated participants to a group by
opening the next sealed envelope in the se-
quence”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label trial.
Participants’ performance, including at-
tending health facilities and adherence to
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treatment, could be influenced by knowing
that they were being part of the experimen-
tal arm of a research study. This could have
an effect on all the primary and secondary
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary and secondary outcomes were ob-
jectively assessed and did not rely on self-re-
ports. Therefore, the risk of detection bias
is low
Incomplete outcome data (attrition bias) Low risk Outcome group: all/quote: ”Patients were
analysed according to their randomization
group following an intention-to-treat pro-
tocol”
LTFUwere 8.8% in the intervention group
and 7.3% in the control group. As rates
were low and similar in both groups, the
risk of attrition bias is low
Incomplete outcome data (attrition bias)
Mortality
Low risk LTFU were low and there were not signif-
icant different across groups. Therefore, it
is unlikely that attrition could bias the es-
timate effect of mortality
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were pre-
specified in the protocol. Therefore the risk
of reporting bias is low
Other bias Low risk No other sources of bias were identified.
McNairy 2017
Methods Open-label cluster-RCT. 10 units were selected from a total of 11 existing secondary-
levelHIV clinics in Swaziland (today known as eSwatini). These units were pair-matched
by implementing partner, location and clinic size
Participants 2550 individuals from 10 clinics
Inclusion criteria
• Age ≥ 18 years.
• Testing HIV-positive at an HTC site within a SU.
• Willing to be referred to an HIV care clinic associated with the SU.
• Willing to provide locator information.
• Willing to adhere to study procedures, including a baseline interview, home-based
interviews at 1 and 12 months after study enrolment; home-based CD4+ count
assessment 12 months after enrolment, and abstraction of data from their medical
records.
• Able to provide informed consent.
Exclusion criteria
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• Planning on leaving the community where they currently reside in the next 12
months for a period > 6 months.
• Enrolled in HIV care in the past 6 months at any HIV care clinic.
• Currently on ART.
• Initiated ART (for any duration) in the past 6 months at any HIV care clinic.
• Does not speak or understand English or si-Swati.
• Reports being currently pregnant at time of study enrolment.
Interventions Intervention arm - CIS: participants received a multi component strategy of 5 evidence-
based interventions
• POC CD4+ count.
• Accelerated ART initiation.
• Cellular phone visit reminders.
• Health education packages.
• Non-cash FIs.
Control arm: managed according to country guidelines.
• Received post-test counselling.
• Referred to an HIV clinic using a national referral form.
• At first HIV clinic visit participants have:
◦ clinical assessment
◦ blood drawn for a CD4+ count test
◦ hematology tests
◦ chemistry tests
◦ instructions to return 1-2 weeks later for test results.
• At return visit, participants eligible for ART according to then prevailing national
guidelines (i.e. with a CD4+ count ≤ 350 cells/mm3)
◦ have first of 3 counselling sessions
◦ are instructed to return to the clinic every month for 6 months and then
every 3 months, if they are stable on treatment.
• Participants ineligible for ART
◦ instructed to return to clinic every 3 months for follow-up.
• Peer counsellors are encouraged to call participants within 7 days of a missed
clinic appointment.
All participants prescribed cotrimoxazole prophylaxis, and condoms, and health infor-
mational materials made available in the clinics
Outcomes Primary outcome
• Linkage to HIV care within 1 month of HIV testing.
• Retention in care at 12 months from HIV testing.
Secondary outcomes
• Time to linkage of care.
• ART eligibility.
• ART initiation.
• Time to ART initiation.
• Viral suppression among participants on ART for at least 6 months.
• Death at 12 months.
• LTFU at 12 months.
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Matched study units were ran-
domised by a computerized random num-
ber generator to the CIS or standard care
(SC) study arm”
Allocation concealment (selection bias) Low risk This is a cluster-RCT. Clusters were ran-
domized before participants were recruited
and therefore allocation concealment was
not possible. Possible bias due to baseline
imbalances are described below
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label trial. The fact that
the personnel in the clinics and the partic-
ipants knew that they were taking part in
an experimental trial could have had an im-
pact on the primary outcomes (linkage of
care and retention in care) as well as on the
secondary outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcomes were objective and not
susceptible to interpretation of assessors.
Therefore, the risk of detection bias is low
Incomplete outcome data (attrition bias) Low risk There were high rates of LTFU (29% in
intervention group and 49% in control).
However it is unlikely that attrition could
bias the estimate of effect of the outcomes
of retention in care, uptake of ART and
virological suppression
Incomplete outcome data (attrition bias)
Mortality
High risk LTFU rates were > 25% in both groups and
significantly higher in the control arm.This
could have had an impact on the estimate of
effect of the primary outcome of mortality
Selective reporting (reporting bias) Low risk Outcomes were pre-specified in the proto-
col and reported in the study. There were
some outcomes not reported, but this is
likely due incomplete data rather than se-
lective reporting
Other bias Low risk We did not identify any other risks of bias.
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Recruitment bias High risk Clinics were matched by various character-
istics, including setting (urban and rural).
There is not enough information to know
where exactly the clinics were situated. But
there is a possibility that PLWH decided
to attend a clinic with the intervention be-
cause they knew of the package of care that
was offered
Baseline comparison concerns Low risk Overall, there were no big baseline imbal-
ances. Lower weekly income in the inter-
vention group and higher rate of unem-
ployment, but significantly closer to the
clinics than those in the control group
Correct statistical analysis Low risk Study authors took clustering into account
and adjusted the results using appropriate
statistical methods
Loss of clusters Low risk All clinics randomised were included in the
final analysis
Contamination Low risk There is no possible herd effect that could
make those PLWH who are closer to in-
tervention clinics less likely to develop the
outcomes
Rosen 2016
Methods Open-label RCT in South Africa
Participants 463 participants were recruited from 2 sector outpatient clinics. 1 site was a primary
health clinic serving an urban informal settlement population on the edge of Johannes-
burg. The second was a large hospital-based HIV clinic serving an urban formal and
informal population within Johannesburg
Inclusion criteria
• Adult patients (> 18 years).
• Tested HIV-positive at study site’s outpatient testing service or antenatal clinic on
day of study enrolment or previously tested HIV-positive but making first visit to study
site for HIV-related care or antenatal care for the current pregnancy.
• Eligible for ART under prevailing South African guidelines.
Exclusion criteria
• Currently or previously on ART (3-drug combination; previous prevention of
mother-to-child transmission (PMTCT) regimen exposure for an earlier pregnancy is
not an exclusion criterion).
• Stated intention to seek further HIV or antenatal care at another site, not at the
study site.
• Not physically or emotionally able to participate in the study, in the opinion of
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the investigators.
• Not willing or able to provide written informed consent to participate in the study.
• Previously screened for the same study.
Interventions Intervention
• All the normal procedures (for example, CD4+ count, TB symptom screen and
test...), including ART initiation, were carried out during the first clinic visit.
Control arm
• Standard care according to South African guidelines.
• 6 clinic visits before ARTs are dispensed.
Outcomes Primary outcome
• Viral suppression at 10 months.
Secondary outcomes
• Retention in care at 10 months.
• Initiation of treatment within 90 days of study enrolment.
• Uptake of treatment within 180 days.
• Time to treatment initiation.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Participants were individually randomised
1:1 to either rapid treatment initiation or standard-
of-care treatment initiation, using block randomiza-
tion in blocks of 6”
Although they mention block randomization, they
do not describe the methods used to generate se-
quence generation. Therefore, it is unclear if the se-
quence generation method was truly random
Allocation concealment (selection bias) Low risk Quote: “Sealed, opaque envelopes containing the al-
locations were prepared by the local principal inves-
tigator and numbered sequentially. The envelopes
were kept in sequential, numbered order at the study
sites. After obtaining written informed consent, the
study assistant opened the next sequentially num-
bered envelope to reveal the allocation.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from text: “RapIT (Rapid Initiation of Treat-
ment) was an unblinded, individually randomised,
controlled trial of a service delivery intervention.”
This trial was unblinded and it could cause an im-
provement of uptake and adherence to ART in those
participants allocated to the experimental arm be-
cause they were aware that they were part of the ex-
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perimental group. A hugely improved standard care
was achieved in the intervention arm. The increase
in uptake and adherence could affect all the out-
comes measured, including virological suppression,
causing performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcomes were assessed through retrospective
electronic medical records. Furthermore, the out-
comes were objective and not self-reported. For this
reason, it is unlikely that they were subject to detec-
tion bias
Incomplete outcome data (attrition bias) Low risk LTFU was 19% in the rapid arm and 36% in the
control arm.
Although LTFU rates were high and not balanced
across groups, authors assumed that those LTFUhad
a negative outcome: “Finally, to confirm that no im-
balance was created by excluding patients after ran-
domization for reasons other than ineligibility for
ART or evidence of a previous eligible CD4 count,
we conducted sensitivity analysis incorporating the
excluded patients and assigning each a negative out-
come”
It is reasonable to assume that PLWH who were
LTFU were not retained in care, did not start ART
and were not virally suppressed
Incomplete outcome data (attrition bias)
Mortality
High risk LTFU was 19% in the rapid arm and 36% in the
control arm.
LTFU was significantly higher in the control arm.
This could have had an impact on the estimate of
effect of the primary outcome of mortality
Selective reporting (reporting bias) Low risk The outcomes reported were pre-specified in the
protocol. Not all the outcomes in the protocol were
reported in this paper. This is likely due to the trial
still being ongoing
Other bias High risk The study included participants who accessed the
clinic for a CD4 count. This means that they knew
their diagnosis in advance before being enrolled in
the study. This is a significantly different population
compared with the ones that the review is interested
(people who have been just diagnosed with HIV)
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Methods Individual RT in South Africa
Participants 717 participants were recruited from 3 primary health clinics operating under control of
the North West Provincial Department of Health, from 3 separate provinces (Gauteng
Province, Free State Province and North West Province)
Inclusion criteria
• Adults aged ≥ 18 years.
• Positive HIV test.
Exclusion criteria
• Not being able to be followed up at the clinics for at least 12 months after
treatment initiation.
• CD4 count > 350 cells/mL.
Interventions Intervention arm
• POC testing for HIV.
• CD4 count.
• Liver and kidney function.
• Expedited TB testing.
• Participants eligible for ART were offered ART initiation on the same day of
presentation.
Control arm
• Standard care as per South African national guidelines.
• ART initiation between 14-21 days after presentation.
Outcomes Primary outcomes
• Proportion of PLWH initiating ART.
• Median time to ART initiation.
• Retention in ART care at 6 and 12 months.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A pooled-box randomization was performed
using an automated web-based algorithm that gener-
ated unique numbers with allocation for an anticipated
1000 participants to either the SC or POC arm (500
to SC and 500 to POC).”
Allocation concealment (selection bias) Unclear risk Study authors do not mention methods of allocation
concealment (for example, use of opaque, sealed en-
velopes)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were aware of the allocation
arm of participants. If participants knew their alloca-
tion arm, they may have been more likely to uptake
ARTor to attend follow-up visits, comparedwith those
in the control arm, affecting the outcomes of “Reten-
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tion in care” and “ART initiation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study authors do not mention if outcome assessment
was blinded. However, the nature of the outcomes and
the fact that they were assessed objectively means that
the risk of detection bias is low
Incomplete outcome data (attrition bias) Low risk LTFU rates were similar in both arms (68% in both
arms at the end of the study). Although these rates are
high, they are unlikely to have caused attrition bias for
the two primary outcomes: ART initiation and reten-
tion in care
Incomplete outcome data (attrition bias)
Mortality
Low risk Many of the LTFU participants might have died and
theremight have beenunder-ascertainment of themor-
tality outcome: the study did however make additional
efforts to determinemortality: “Records of participants
not attending scheduled patient visits were logged and
study staff made attempts to contact participants tele-
phonically to ascertain location. Further follow-up was
obtained, where possible, from the National Popula-
tionRegister (vital register) and theCentral DataWare-
house of the NHLS”. Given these efforts and the fact
that overall mortality was about 3%-5%, which ap-
proximates mortality in cohorts where there is com-
plete vital status ascertainment through tracing - we
judged this outcome low risk of bias
Selective reporting (reporting bias) Low risk There was no information about pre-specified out-
comes, as no reference to the protocol is found in the
study. However all relevant and non-significant out-
comes were reported
Other bias Low risk We did not identify any other risks of bias.
Abbreviations: ART: antiretroviral therapy; CIS: combination intervention strategy; FI: financial incentive; HTC: HIV testing and
counselling; LTFU: loss/lost to follow-up; PLWH: people living with HIV; POC: point-of-care; RCT: randomized controlled trial;
RNA: ribonucleic acid; SMS: short message service; SC: standard care; SU: study unit; TB: tuberculosis; VCT: voluntary counselling
and testing.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Achhra 2017 Wrong intervention. ART initiation is not based on time since diagnosis, but on CD4 count
Bisson 2013 Wrong patient population. They only included PLWH with cryptococcal meningitis
Blanc 2011 Wrong patient population. They only included PLWH with TB.
Boulware 2014 Wrong patient population. They only included PLWH with TB.
Danel 2015 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Degu 2012 Wrong patient population. They only included PLWH with TB.
Ford 2016 Wrong study design. Not a RCT
Grant 2010 Wrong study design. Not a RCT
Havlir 2011 Wrong patient population. They only included PLWH with cryptococcal meningitis
Iwuji 2017 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Koenig 2011 Wrong design. Cost-effectiveness analysis
Larmarange 2016 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Laurelliard 2013 Wrong patient population. They only included PLWH with TB.
Long 2017 Wrong study design. Cost-defectiveness analysis
Makadzange 2010 Wrong patient population. They only included PLWH with cryptococcal meningitis
Plazy 2016 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Sabapathy 2017 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Temprano 2015 Wrong intervention. ART initiation was not based on time since diagnosis, but on CD4 count
Wu 2017 Wrong intervention. Rapid ART not part of the intervention
Abbreviations: ART: antiretroviral therapy; PLWH: people living with HIV; RCT: randomized controlled trial; TB: tuberculosis.
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Characteristics of ongoing studies [ordered by study ID]
Maskew 2018
Trial name or title Same-day ART initiation in the slate trial in South Africa: preliminary results
Methods Individual RCT
Participants PLWH attending 3 public outpatient clinics
Interventions Intervention
• A clinical algorithm (SLATE) that allows nurses to determine eligibility for immediate ART dispensing.
Control
• Standard care.
Outcomes ART initiation ≤ 28 days of study
Starting date 6 March 2017
Contact information sbrosen@bu.edu
Notes
NCT02776254
Trial name or title Differentiated care for improved health systems efficiency and health outcomes in Zambia (CommART)
Methods Parallel-RCT
Participants Inclusion criteria
• HIV-positive adolescents and adults (> 14 years of age).
• Last CD4 count (obtained within the last six months) > 200 cells/µL.
• Not acutely ill.
• For CAGs, UAGs, and fast-track models: on ART for at least 6 months.
• For the START model: ART naïve and meet the Zambian HIV guidelines for treatment initiation.
Exclusion criteria
• For CAGs, UAGs: inability to participate in the group activities due to cognition deficits or mental
illness.
• Unable to provide consent or unwilling to participate in study.
• Pregnancy.
Interventions The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing
and results, streamlined adherence counselling, and quicker initiation of life-long ART to patients enrolling
in HIV care and treatment services
Outcomes Primary outcome: Retention in care at 12 months
Starting date March 2016
Contact information Izukanji.Sikazwe@cidrz.org
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Notes
PACTR201706002322546a
Trial name or title Early initiation ART adherence clubs versus standard care to enhance patient retention in care: a pilot study
Methods Parallel-RCT
Participants PLWH
Inclusion criteria
• Age > 18 years.
• ART-naïve.
• Started on ART on day of HIV diagnosis.
• CD4 > 200 cells/µL.
• Normal baseline blood tests (creatinine, haemoglobin, liver function tests, hepatitis B surface antigen).
Exclusion criteria
• Age < 18 years.
• Previously on ART.
• Presumed TB or receiving TB treatment.
• Pregnant women.
• Current comorbidity or chronic illness that is unstable (hypertension, diabetes, epilepsy, cancer, mental
illness) or other disease that required routine and frequent clinical management.
• Contraindicatd for fixed-dose combination ART.
• Refused same-day ART initiation.
• CD4 count < 200 cells/µL.
• Anaemia.
• Abnormal kidney or liver function tests.
• Severe side effects to ART.
Interventions Intervention
• Early ART initiation clubs (early initiation clubs consist of 20-30 people with HIV who have just been
diagnosed and are starting ART).
Control
• Standard care.
Outcomes Proportion of participants retained in care after 6 months following ART initiation
Starting date 1 April 2017
Contact information joels@witkoppen.co.za
Notes
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Trial name or title Early initiation ART adherence clubs versus standard care to enhance patient retention in care: a pilot study
Methods Parallel-RCT
Participants PLWH
Inclusion criteria
• Age > 18 years.
• ART-naïve.
• Started on ART on day of HIV diagnosis.
• CD4 > 200 cells/µL.
• Normal baseline blood tests (creatinine, haemoglobin, liver function tests, hepatitis B surface antigen).
Exclusion criteria
• Age < 18 years.
• Previously on ART.
• Presumed TB or receiving TB treatment.
• Pregnant women.
• Current comorbidity or chronic illness that is unstable (hypertension, diabetes, epilepsy, cancer, mental
illness) or other disease that required routine and frequent clinical management.
• Contraindicatd for fixed-dose combination ART.
• Refused same-day ART initiation.
• CD4 count < 200 cells/µL.
• Anaemia.
• Abnormal kidney or liver function tests.
• Severe side effects to ART.
Interventions Intervention
• Early ART initiation clubs (early initiation clubs consist of 20-30 people with HIV who have just been
diagnosed and are starting ART).
Control
• Standard care.
Outcomes Proportion of participants retained in care after 6 months following ART initiation
Starting date 1 April 2017
Contact information joels@witkoppen.co.za
Notes
Rosen 2017
Trial name or title Simplified algorithm for treatment eligibility (SLATE)
Methods Open-label RCT
Participants Inclusion
• Adult patients (> 18 years) (initiating children on ART is likely to require additional information,
making the SLATE algorithm less applicable to paediatric populations)
• Confirmed HIV-positive test result at any time (may have been diagnosed previously)
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• Not currently on ART (3-drug combination)
• Presented at the study clinic for any HIV-related reason, including an HIV test, pre-ART monitoring,
or ART initiation
Interventions Intervention
• Immediate treatment initiation under the intervention algorithm (SLATE).
Control
• Standard procedures for initiating ART for HIV.
Outcomes Primary outcomes
• Proportion of participants initiated on ART within 28 days of study enrolment.
• Proportion of participants who initiate ART within 28 days of study enrolment and are alive, in care,
and retained on ART 8 months after study enrolment.
Secondary outcomes
• Proportion of participants who initiate ART within 14 days of study enrolment.
• Proportion of participants who are virally suppressed according to local guidelines within 8 months of
study enrolment.
• Retention defined as > 1 month late for last scheduled visit.
• Retention defined as > 3 months late for last scheduled visit.
• Proportions of HIV-positive people presenting at study clinics and not yet on ART who are eligible
and ineligible for immediate initiation using SLATE algorithm criteria.
• Reasons for ineligibility for immediate initiation, among those found ineligible in the intervention arm.
• Average time to ART initiation (days) for each arm.
Starting date 6 March 2017
Contact information sbrosen@bu.edu
Notes
Sikazwe 2018
Trial name or title A streamlined ART initiation algorithm of care reduces time to ART
Methods Unknown
Participants Participants were from 2 urban public health facilities
Interventions Intervention
• Revised ART initiation approach with same-day readiness assessment.
• POC CD4 assessment and ART initiation.
Control
• Standard care.
Outcomes • Mortality.
• Time to ART initiation.
Starting date Unknown
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Contact information Izukanji.Sikazwe@cidrz.org
Notes
Abbreviations: ART: antiretroviral therapy; CAG: community adherence group; PLWH: people living with HIV; POC: point-of-care;
RCT: randomized controlled trial; TB: tuberculosis; UAG: urban adherence group.
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D A T A A N D A N A L Y S E S
Comparison 1. Rapid ART versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 7 Risk Ratio (Fixed, 95% CI) 0.72 [0.51, 1.01]
1.1 RCT 4 Risk Ratio (Fixed, 95% CI) 0.59 [0.34, 1.02]
1.2 Cluster-RCT 3 Risk Ratio (Fixed, 95% CI) 0.81 [0.52, 1.24]
2 Virological suppression at 12
months
4 Risk Ratio (Fixed, 95% CI) 1.18 [1.10, 1.27]
2.1 RCT 3 Risk Ratio (Fixed, 95% CI) 1.24 [1.12, 1.37]
2.2 Cluster-RCT 1 Risk Ratio (Fixed, 95% CI) 1.13 [1.02, 1.25]
3 Retention in care 6 Risk Ratio (Random, 95% CI) 1.22 [1.11, 1.35]
3.1 RCT 4 Risk Ratio (Random, 95% CI) 1.16 [1.06, 1.28]
3.2 Cluster-RCT 2 Risk Ratio (Random, 95% CI) 1.37 [1.20, 1.57]
4 Uptake of ART at 90 days 4 Risk Ratio (Random, 95% CI) 1.31 [1.18, 1.45]
4.1 RCT 3 Risk Ratio (Random, 95% CI) 1.41 [1.12, 1.76]
4.2 Cluster-RCT 1 Risk Ratio (Random, 95% CI) 1.27 [1.25, 1.29]
5 Uptake of ART at 12 months 4 Risk Ratio (Fixed, 95% CI) 1.09 [1.06, 1.12]
5.1 RCT 2 Risk Ratio (Fixed, 95% CI) 1.09 [1.06, 1.12]
5.2 Cluster-RCT 2 Risk Ratio (Fixed, 95% CI) 1.18 [1.04, 1.35]
6 Treatment modification 2 977 Risk Ratio (M-H, Random, 95% CI) 7.89 [0.76, 81.74]
Comparison 2. Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 7 Risk Ratio (Fixed, 95% CI) Subtotals only
1.1 Same-day ART 4 Risk Ratio (Fixed, 95% CI) 0.59 [0.34, 1.02]
1.2 ART offered within 7 days 1 Risk Ratio (Fixed, 95% CI) 0.80 [0.46, 1.39]
1.3 ART offered at first clinic
visit
1 Risk Ratio (Fixed, 95% CI) 0.87 [0.40, 1.89]
1.4 ART offered within 14
days
1 Risk Ratio (Fixed, 95% CI) 0.65 [0.14, 3.02]
2 Virological suppression at 12
months
4 Risk Ratio (Fixed, 95% CI) Subtotals only
2.1 Same-day ART 3 Risk Ratio (Fixed, 95% CI) 1.24 [1.12, 1.37]
2.2 ART offered within 14
days
1 Risk Ratio (Fixed, 95% CI) 1.13 [1.02, 1.25]
3 Retention in care 6 Risk Ratio (Fixed, 95% CI) Subtotals only
3.1 Same-day ART 4 Risk Ratio (Fixed, 95% CI) 1.15 [1.08, 1.23]
3.2 ART offered within 7 days 1 Risk Ratio (Fixed, 95% CI) 1.48 [1.18, 1.86]
3.3 ART offered at first clinic
visit
1 Risk Ratio (Fixed, 95% CI) 1.32 [1.12, 1.56]
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4 Uptake of ART at 90 days 4 Risk Ratio (Random, 95% CI) Subtotals only
4.1 Same-day ART 3 Risk Ratio (Random, 95% CI) 1.41 [1.12, 1.76]
4.2 ART offered within 14
days
1 Risk Ratio (Random, 95% CI) 1.27 [1.25, 1.29]
5 Uptake of ART at 12 months 4 Risk Ratio (Random, 95% CI) Subtotals only
5.1 Same-day ART 2 Risk Ratio (Random, 95% CI) 1.12 [1.02, 1.24]
5.2 ART offered within 7 days 1 Risk Ratio (Random, 95% CI) 1.16 [0.96, 1.40]
5.3 ART offered at first clinic
visit
1 Risk Ratio (Random, 95% CI) 1.20 [1.00, 1.44]
Comparison 3. Rapid ART versus standard care, virological suppression: analysis by method of measurement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Virological suppression at 12
months in participants on ART
for at least 6 months
1 Risk Ratio (Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Rapid ART versus standard care, Outcome 1 Mortality.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 1 Mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Koenig 2017 -0.6675 (0.3799) 21.0 % 0.51 [ 0.24, 1.08 ]
Labhardt 2018 1.6094 (1.5445) 1.3 % 5.00 [ 0.24, 103.19 ]
Rosen 2016 -1.9301 (1.5084) 1.3 % 0.15 [ 0.01, 2.79 ]
Stevens 2017 -0.3902 (0.4644) 14.1 % 0.68 [ 0.27, 1.68 ]
Subtotal (95% CI) 37.7 % 0.59 [ 0.34, 1.02 ]
Heterogeneity: Chi2 = 3.00, df = 3 (P = 0.39); I2 =0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 Cluster-RCT
Amanyire 2016 (1) -0.4308 (0.7833) 4.9 % 0.65 [ 0.14, 3.02 ]
0.01 0.1 1 10 100
Favours rapid ART Favours standard care
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Elul 2017 (2) -0.1393 (0.3965) 19.3 % 0.87 [ 0.40, 1.89 ]
McNairy 2017 -0.2231 (0.2823) 38.1 % 0.80 [ 0.46, 1.39 ]
Subtotal (95% CI) 62.3 % 0.81 [ 0.52, 1.24 ]
Heterogeneity: Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 100.0 % 0.72 [ 0.51, 1.01 ]
Heterogeneity: Chi2 = 3.90, df = 6 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
Favours rapid ART Favours standard care
(1) Based on a random sample of participants which was inverse probability weighted
(2) CIS
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Analysis 1.2. Comparison 1 Rapid ART versus standard care, Outcome 2 Virological suppression at 12
months.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 2 Virological suppression at 12 months
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Koenig 2017 0.1673 (0.0668) 29.5 % 1.18 [ 1.04, 1.35 ]
Labhardt 2018 0.384 (0.1455) 6.2 % 1.47 [ 1.10, 1.95 ]
Rosen 2016 0.2307 (0.0906) 16.1 % 1.26 [ 1.05, 1.50 ]
Subtotal (95% CI) 51.8 % 1.24 [ 1.12, 1.37 ]
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 Cluster-RCT
Amanyire 2016 0.1222 (0.0523) 48.2 % 1.13 [ 1.02, 1.25 ]
Subtotal (95% CI) 48.2 % 1.13 [ 1.02, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Total (95% CI) 100.0 % 1.18 [ 1.10, 1.27 ]
Heterogeneity: Chi2 = 3.45, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
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Analysis 1.3. Comparison 1 Rapid ART versus standard care, Outcome 3 Retention in care.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 3 Retention in care
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 RCT
Koenig 2017 0.1044 (0.0427) 27.1 % 1.11 [ 1.02, 1.21 ]
Labhardt 2018 0.2578 (0.1071) 13.2 % 1.29 [ 1.05, 1.60 ]
Rosen 2016 0.2215 (0.0647) 21.5 % 1.25 [ 1.10, 1.42 ]
Stevens 2017 -0.0219 (0.1408) 9.1 % 0.98 [ 0.74, 1.29 ]
Subtotal (95% CI) 70.8 % 1.16 [ 1.06, 1.28 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Cluster-RCT
Elul 2017 (1) 0.2776 (0.0838) 17.2 % 1.32 [ 1.12, 1.56 ]
McNairy 2017 (2) 0.392 (0.1156) 12.0 % 1.48 [ 1.18, 1.86 ]
Subtotal (95% CI) 29.2 % 1.37 [ 1.20, 1.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
Total (95% CI) 100.0 % 1.22 [ 1.11, 1.35 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.83, df = 5 (P = 0.05); I2 =54%
Test for overall effect: Z = 4.07 (P = 0.000046)
Test for subgroup differences: Chi2 = 3.97, df = 1 (P = 0.05), I2 =75%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
(1) CIS arm only
(2) Regardless of ART eligibility and uptake
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Analysis 1.4. Comparison 1 Rapid ART versus standard care, Outcome 4 Uptake of ART at 90 days.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 4 Uptake of ART at 90 days
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 RCT
Koenig 2017 0.1158 (0.0188) 31.2 % 1.12 [ 1.08, 1.16 ]
Labhardt 2018 0.7591 (0.137) 10.5 % 2.14 [ 1.63, 2.79 ]
Rosen 2016 0.2914 (0.0464) 26.2 % 1.34 [ 1.22, 1.47 ]
Subtotal (95% CI) 67.8 % 1.41 [ 1.12, 1.76 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 32.36, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.96 (P = 0.0030)
2 Cluster-RCT
Amanyire 2016 0.239 (0.0081) 32.2 % 1.27 [ 1.25, 1.29 ]
Subtotal (95% CI) 32.2 % 1.27 [ 1.25, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 29.51 (P < 0.00001)
Total (95% CI) 100.0 % 1.31 [ 1.18, 1.45 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 53.90, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.98 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
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Analysis 1.5. Comparison 1 Rapid ART versus standard care, Outcome 5 Uptake of ART at 12 months.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 5 Uptake of ART at 12 months
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 RCT
Koenig 2017 0.0787 (0.0154) 89.1 % 1.08 [ 1.05, 1.12 ]
Stevens 2017 0.1821 (0.0583) 6.2 % 1.20 [ 1.07, 1.34 ]
Subtotal (95% CI) 95.3 % 1.09 [ 1.06, 1.12 ]
Heterogeneity: Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 5.74 (P < 0.00001)
2 Cluster-RCT
Elul 2017 (1) 0.1823 (0.093) 2.4 % 1.20 [ 1.00, 1.44 ]
McNairy 2017 0.1484 (0.0966) 2.3 % 1.16 [ 0.96, 1.40 ]
Subtotal (95% CI) 4.7 % 1.18 [ 1.04, 1.35 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 100.0 % 1.09 [ 1.06, 1.12 ]
Heterogeneity: Chi2 = 4.38, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 6.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.38, df = 1 (P = 0.24), I2 =27%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
(1) CIS arm only
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Analysis 1.6. Comparison 1 Rapid ART versus standard care, Outcome 6 Treatment modification.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 1 Rapid ART versus standard care
Outcome: 6 Treatment modification
Study or subgroup Rapid ART Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Koenig 2017 (1) 13/347 0/356 43.5 % 27.70 [ 1.65, 464.14 ]
Labhardt 2018 3/137 1/137 56.5 % 3.00 [ 0.32, 28.48 ]
Total (95% CI) 484 493 100.0 % 7.89 [ 0.76, 81.74 ]
Total events: 16 (Rapid ART), 1 (Standard care)
Heterogeneity: Tau2 = 1.20; Chi2 = 1.71, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours rapid ART Favours standard care
(1) No POCT U%Es available - changed regimen on day 3
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Analysis 2.1. Comparison 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation,
Outcome 1 Mortality.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome: 1 Mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Same-day ART
Koenig 2017 -0.6675 (0.38) 55.8 % 0.51 [ 0.24, 1.08 ]
Labhardt 2018 1.6094 (1.5444) 3.4 % 5.00 [ 0.24, 103.17 ]
Rosen 2016 -1.9303 (1.5115) 3.5 % 0.15 [ 0.01, 2.81 ]
Stevens 2017 -0.3902 (0.4644) 37.3 % 0.68 [ 0.27, 1.68 ]
Subtotal (95% CI) 100.0 % 0.59 [ 0.34, 1.02 ]
Heterogeneity: Chi2 = 3.00, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 ART offered within 7 days
McNairy 2017 -0.2231 (0.2822) 100.0 % 0.80 [ 0.46, 1.39 ]
Subtotal (95% CI) 100.0 % 0.80 [ 0.46, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
3 ART offered at first clinic visit
Elul 2017 -0.1393 (0.3966) 100.0 % 0.87 [ 0.40, 1.89 ]
Subtotal (95% CI) 100.0 % 0.87 [ 0.40, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
4 ART offered within 14 days
Amanyire 2016 -0.4308 (0.7833) 100.0 % 0.65 [ 0.14, 3.02 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.14, 3.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.90, df = 3 (P = 0.83), I2 =0.0%
0.01 0.1 1 10 100
Favours standard care Favours rapid ART
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Analysis 2.2. Comparison 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation,
Outcome 2 Virological suppression at 12 months.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome: 2 Virological suppression at 12 months
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Same-day ART
Koenig 2017 0.1673 (0.0668) 57.0 % 1.18 [ 1.04, 1.35 ]
Labhardt 2018 0.384 (0.1455) 12.0 % 1.47 [ 1.10, 1.95 ]
Rosen 2016 0.2307 (0.0906) 31.0 % 1.26 [ 1.05, 1.50 ]
Subtotal (95% CI) 100.0 % 1.24 [ 1.12, 1.37 ]
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 ART offered within 14 days
Amanyire 2016 0.1222 (0.0523) 100.0 % 1.13 [ 1.02, 1.25 ]
Subtotal (95% CI) 100.0 % 1.13 [ 1.02, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
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Analysis 2.3. Comparison 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation,
Outcome 3 Retention in care.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome: 3 Retention in care
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Same-day ART
Koenig 2017 0.1044 (0.0427) 59.3 % 1.11 [ 1.02, 1.21 ]
Labhardt 2018 0.2578 (0.1071) 9.4 % 1.29 [ 1.05, 1.60 ]
Rosen 2016 0.2215 (0.0647) 25.8 % 1.25 [ 1.10, 1.42 ]
Stevens 2017 -0.0219 (0.1408) 5.5 % 0.98 [ 0.74, 1.29 ]
Subtotal (95% CI) 100.0 % 1.15 [ 1.08, 1.23 ]
Heterogeneity: Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 ART offered within 7 days
McNairy 2017 0.392 (0.1156) 100.0 % 1.48 [ 1.18, 1.86 ]
Subtotal (95% CI) 100.0 % 1.48 [ 1.18, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
3 ART offered at first clinic visit
Elul 2017 0.2776 (0.0838) 100.0 % 1.32 [ 1.12, 1.56 ]
Subtotal (95% CI) 100.0 % 1.32 [ 1.12, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00092)
Test for subgroup differences: Chi2 = 6.02, df = 2 (P = 0.05), I2 =67%
0.01 0.1 1 10 100
Favours standard care Favours rapid ART
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Analysis 2.4. Comparison 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation,
Outcome 4 Uptake of ART at 90 days.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome: 4 Uptake of ART at 90 days
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Same-day ART
Koenig 2017 0.1158 (0.0188) 38.4 % 1.12 [ 1.08, 1.16 ]
Labhardt 2018 0.7591 (0.137) 25.0 % 2.14 [ 1.63, 2.79 ]
Rosen 2016 0.2914 (0.0464) 36.5 % 1.34 [ 1.22, 1.47 ]
Subtotal (95% CI) 100.0 % 1.41 [ 1.12, 1.76 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 32.36, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.96 (P = 0.0030)
2 ART offered within 14 days
Amanyire 2016 0.239 (0.0081) 100.0 % 1.27 [ 1.25, 1.29 ]
Subtotal (95% CI) 100.0 % 1.27 [ 1.25, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 29.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
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Analysis 2.5. Comparison 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation,
Outcome 5 Uptake of ART at 12 months.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 2 Rapid ART versus standard care: subgroup analysis by time of ART initiation
Outcome: 5 Uptake of ART at 12 months
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Same-day ART
Koenig 2017 0.0787 (0.0154) 64.8 % 1.08 [ 1.05, 1.12 ]
Stevens 2017 0.1821 (0.0583) 35.2 % 1.20 [ 1.07, 1.34 ]
Subtotal (95% CI) 100.0 % 1.12 [ 1.02, 1.24 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 2.33 (P = 0.020)
2 ART offered within 7 days
McNairy 2017 0.1484 (0.0966) 100.0 % 1.16 [ 0.96, 1.40 ]
Subtotal (95% CI) 100.0 % 1.16 [ 0.96, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 ART offered at first clinic visit
Elul 2017 0.1823 (0.093) 100.0 % 1.20 [ 1.00, 1.44 ]
Subtotal (95% CI) 100.0 % 1.20 [ 1.00, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Chi2 = 0.44, df = 2 (P = 0.80), I2 =0.0%
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
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Analysis 3.1. Comparison 3 Rapid ART versus standard care, virological suppression: analysis by method of
measurement, Outcome 1 Virological suppression at 12 months in participants on ART for at least 6 months.
Review: Rapid initiation of antiretroviral therapy for people living with HIV
Comparison: 3 Rapid ART versus standard care, virological suppression: analysis by method of measurement
Outcome: 1 Virological suppression at 12 months in participants on ART for at least 6 months
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
McNairy 2017 -0.0245 (0.0232) 0.98 [ 0.93, 1.02 ]
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours standard care Favours rapid ART
A D D I T I O N A L T A B L E S
Table 1. Antiretroviral treatment and prophylaxis for pregnant women according to the WHO Prevention of mother-to-child
transmission programmes
Options Treatment for pregnant women with CD4 count < 350
cells/mm³
Prophylaxis for pregnant women with CD4 count >
350 cells/mm³
Option A ART started as soon as HIV is diagnosed, continued for
life
Antivirals started as soon as 14 weeks of gestation and con-
tinued until 7 days post-partum
Option B ART started as soon as HIV is diagnosed, continued for
life
Antivirals started as soon as 14 weeks of gestation until
childbirth if not breastfeeding or until one week after ces-
sation of breastfeeding
Option B+ ART initiated as soon as HIV diagnosis and continued for life
Source: WHO 2012.
Abbreviations: ART: antiretroviral therapy; WHO: World Health Organization.
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Table 2. Interventions delivered alongside rapid antiretroviral therapy (ART) in the intervention arm
Study Intervention target
Individuala Health systemb
Health-providers Healthcare structures and pro-
cesses
Amanyire 2016 • ART initiation within 14 days
of eligibility
• Individualized counselling
including assessment of ART
readiness
• Opinion-leader-led training of
healthcare workers on the benefits
of early ART, including lectures,
introduction of revised ‘less strict’
counselling approach, and ART
readiness assessment
• Feedback on ART initiation
rates
• POC HIV diagnosis and CD4
count
• No need for treatment
supporters
• Flexible number of pre-ART
counselling sessions
Elul 2017 • ART initiation at 1st visit after
diagnosis
• Counselling session on day of
presentation
• Mobile phone visit reminders
• Non-cash FIc,d
• Receptionists expedited
PLWH appointments
• Clinicians encouraged to start
ART on 1st clinic visit
• POC HIV diagnosis and CD4
count
• Paper-based referral to on-site
HIV services
• 1st consultation within 1 week
from diagnosis
Koenig 2017 • Same-day ART initiation
• Readiness assessment surveye
• 30-min adherence counselling
• Participants received transport
subsidies per visit
• Social worker: readiness
assessment, adherence counselling
• Physician: physical evaluation
and adherence counselling
• Pharmacist: dispense ART
• POC HIV diagnosis and CD4
count
• No pre-ART clinic visits
• 4 adherence counselling
sessions and OI assessments within
17 days from presentation
Labhardt 2018 • Same-day ART initiation
• Short adherence counselling
• Leaflet with importance of
adherence handed to participant
• 30-day supply of ART if ready
to start, assessed by study nurse
• POC tests, counselling,
readiness assessment and ART
dispensing performed by nurse on
day of HIV diagnosis
• POC HIV diagnosis and CD4
count
• No pre-ART clinic visits
• Longer intervals between
follow-up visits
• Testing, diagnosis, counselling
and ART dispensing at PLWH’s
home
McNairy 2017 • ART initiation within 1 week
of testing
• 2 pre-ART counselling sessions
• Participant provided with
health education package every 3
monthsg
• Mobile phone visit reminders
• Non-cash FIc
• Counsellors: conduct
abbreviated counselling
• HCWs: use checklist to
determine readiness to initiate ART
• POC HIV diagnosis and CD4
count
• Reduced number of pre-ART
counselling sessions
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Table 2. Interventions delivered alongside rapid antiretroviral therapy (ART) in the intervention arm (Continued)
Rosen 2016 • Same-day ART initiation
• Adherence and counsellingf
on day of presentation
• ARVs dispensed on 1st day
• Blood test, TB screening,
physical examination, education,
counselling and ARV dispensing by
study nurse
• Staff received study- and
instrument-specific training
• POC HIV diagnosis and CD4
count
• Rapid TB test
• No-pre ART clinic visits
Stevens 2017 • Same-day ART
• Same-day adherence
counselling
• Staff received instrument-
specific training
• POC CD4 testing and POC
chemistry and haematology testing
• No pre-ART visits
Abbreviations: ART: antiretroviral therapy; ARV: antiretroviral; FI: financial incentive; HCW: healthcare worker; OI: opportunistic
infections; PLWH: people living with HIV; POC: point-of-care; TB: tuberculosis
aThe aim of the intervention is to act on service users.
bThe intervention, rather than acting on service users, acts on different parts of the healthcare system: health workers or the current
health structures and processes.
cPrepaid mobile airtime.
dOnly included in one of the two intervention groups (enhanced combined intervention strategy (CIS+)).
eSurvey adapted from Balfour 2007.
fCounselling session included assessment of readiness to start ART.
gIncluding pillbox, condoms, toothbrush, and toothpaste.
Table 3. Main characteristics of included studies
Study Group Study type Partici-
pants (N)
Median/
mean age
(years)
Gen-
der (% fe-
male)
Median/
mean
CD4-
(cells/mL)
Country
and
setting
Time to
ART initi-
ation
Relevant
re-
view out-
comes re-
ported
Amanyire
2016
I Cluster-
RCT
4747 30 60% 320 Uganda,
urban + ru-
ral
80%
within
14 days af-
ter diagno-
sis
Mortality
Viral sup-
pression
Uptake of
ART
C 7277 31 65% 304 38%
within 14
days
after eligi-
bility con-
firmed
Elul 2017 I (CIS) Cluster-
RCT
557 35 66% NR Mozam-
bique, ur-
ban + rural
Median
time from
diagnosis:
32 days
Mortality
Retention
in care at
12 months
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Table 3. Main characteristics of included studies (Continued)
Uptake of
ART
I (CIS+) 372 34 65% NR
C 474 34 63% NR Median
time from
diagnosis:
63 days
Koenig
2017
I RCT 347 37 48% 249 Haiti, ur-
ban
99% day of
diagnosis
Mortality
Viral sup-
pression
Reten-
tion in care
(12 to 15
months)
Uptake of
ART
C 356 37 51% NR 79% by 1
month af-
ter diagno-
sis
Labhardt
2018
I RCT 137 41 66% 346 Lesotho,
rural
Planned on
day of diag-
nosis
Mortality
Viral sup-
pression
Reten-
tion in care
(11 to 14
months)
Treat-
ment mod-
ification
C 137 38 66% 417 Planned af-
ter 2nd
ART visit
McNairy
2017
I Cluster-
RCT
1096 32 60% 311 Swazi-
land (today
known as
eSwatini),
urban + ru-
ral
Median
time from
diagnosis:
7 days
Mortality
Viral sup-
pression
Retention
in care at
12 months
Uptake of
ART
C 1101 30 58% 285 Median
time from
diagnosis:
14 days
Rosen
2016
I RCT 187 > 18a 55% 224 South
Africa, ur-
ban
72%
started on
enrolment
day
Mortality
Viral sup-
pression
Reten-
tion in care
(5 to 10
months)
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Table 3. Main characteristics of included studies (Continued)
Uptake of
ART
C 190 > 18a 58% 195 58%
within 1
month af-
ter diagno-
sis
Stevens
2017
I RCT 234 37.5 59.1% 200 South
Africa, NR
Me-
dian from
presenta-
tion: 1 days
Mortality
Retention
in care at
12 months
Uptake of
ARTC 198 37.4 62.2% 165.7 Me-
dian from
presen-
tation 26.5
days
Abbreviations: I: intervention; C: control; ART: antiretroviral therapy; CIS: combination intervention strategy; CIS+: enhanced
combination intervention strategy; d: day; N: number; NR: not reported; RCT: randomized controlled trial
aStudy did not report age; inclusion specified over 18 years.
Table 4. Summary of cohort studies investigating the effect of rapid antiretroviral therapy (ART)
Study Country Popula-
tion
(num-
ber of par-
ticipants)
Interven-
tion
and com-
parison
Outcome Summary
Mortality Viral sup-
pression
Uptake Retention Adher-
ence
Lang-
wenya
2018
South
Africa
Pregnant
women
(628)
Same-day
ART initi-
ation ver-
sus delayed
ART
N/A Adjusted
OR of viral
sup-
pression at
delivery in
same-day
ART ver-
sus delayed
ART: 0.78,
(95%CI 0.
43 to 1.43)
P = 0.808
N/A Adjusted
OR of re-
tention
in care at
12 months
post-
partum in
same-day
ART ver-
sus delayed
ART: 1.48,
(95%CI 0.
85 to 1.58)
N/A Same-day
ART
makes lit-
tle to no
differ-
ence in re-
tention or
viral sup-
pression
compared
to delayed
ART in
pregnant
women
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Table 4. Summary of cohort studies investigating the effect of rapid antiretroviral therapy (ART) (Continued)
Oladele
2018
Nigeria An estima-
tion of all
PLWH
in 14 lo-
cal govern-
ment areas
(164,389)
Model A:
same-day
ART initi-
ation
in commu-
nity
Model
B: Referral
for same-
day
ART initi-
ation at
health fa-
cility
N/A N/A Model A
inter-
vention in-
creased up-
take from
216 ART
initiations
to 560; P <
0.001)
No change
over time
in
the Model
B group
N/A N/A Increase in
ART up-
take when
of-
fered in the
commu-
nity com-
pared to fa-
cility refer-
ral
Pilcher
2017
USA Adults
(86)
Same-day
ART initi-
ation ver-
sus delayed
ART
N/A Median
time to vi-
ral
suppres-
sion Same-
day ART:
56 days.
De-
layed ART:
79 days. P
= 0.009
ART up-
take at 90
days
Same-day
ART: 39/
39 (100%)
Delayed
ART: 36/
47 (77%)
LTFU rate
at 6
months
Same-
day ART:
11 (12%)
De-
layed ART:
7 (14.9%)
P = 0.52
N/A Same-day
ART
shows bet-
ter uptake
and faster
viral sup-
pression
compared
to de-
layed ART.
No differ-
ences in re-
tention at
6 months
Ssebunya
2017
Uganda Children
(367)
ART initi-
a-
tion within
7 days of
enrol-
ment ver-
sus ART
initiation >
7 days after
enrolment
At 5 years:
15 deaths
(8.3%) in
early ART
group ver-
sus 27 (14.
4%) in de-
layed
group
P = 0.026
Median
time to vi-
ral
suppres-
sion = 24.
9 months
(95% CI
19.7 to 28.
5
months) in
early ART
group ver-
sus 38.
3 months
(95%CI
31.1 to 44.
5 months)
in delayed
group
N/A At 5 years:
LTFU = 6
(3.3%) in
early ART
group ver-
sus 16 (8.
6%) in de-
layed initi-
ation
group
Adherence
rate = 65
(36.1%) in
early ART
group ver-
sus 45 (34.
2%) in de-
layed
group
Initi-
ating ART
within 7 d
was associ-
ated with
lower mor-
tality; bet-
ter reten-
tion; faster
viral sup-
pression
and possi-
bly better
adherence
than initi-
ating ART
> 7 d after
enrolment
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Table 4. Summary of cohort studies investigating the effect of rapid antiretroviral therapy (ART) (Continued)
Vogt 2017 Zimbabwe Adoles-
cents aged
≥ 10 to <
19 years
(1499)
Com-
pared ART
initiation
between 7
and 14 d
after diag-
nosis with
ART initi-
ation
within: 0-
7 d; 14-1
months; 1-
2 months;
≥ 2
months af-
ter diagno-
sis
Ad-
justed HR
of mortal-
ity at 24
months
ART initi-
ation 0-7 d
versus
7-14 d af-
ter diagno-
sis: 1.59,
95%CI (0.
83 to 3.04)
N/A N/A Adjusted
HR of re-
tention at
24 months
ART ini-
tiation 0-7
days versus
7-14 days
after diag-
nosis: 1.02
(95%CI 0.
62 to 1.67)
N/A Initi-
ating ART
within 7 d
after diag-
nosis
showed no
difference
in mortal-
ity or re-
tention in
care com-
pared to
initi-
ating ART
between 7-
14 d after
diagnosis
Zhao 2018 China Adults (34,
581)
Immediate
ART: ART
initia-
tion within
30 d of eli-
gibility
De-
layed ART:
ART initi-
ation > 30
d after eli-
gibility
No ART:
no ART
initiation
HR
of mortal-
ity: Imme-
diate ART
versus no
ART: 0.37,
(95%CI 0.
23 to 0.58)
;
De-
layed ART
versus no
ART: 0.74,
(95%CI 0.
57 to 0.98)
N/A N/A N/A N/A Imme-
diate ART
showed
a stronger
reduction
in mor-
tality com-
pared
to delayed
ART
Abbreviations: ART: antiretroviral therapy; HR: hazard ratio; LTFU: loss to follow-up; N/A: not applicable; OR: odds ratio.
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (PubMed)
Search Query
#11 Search #5 AND #8 AND #9 AND #10
#10 Search #3 OR #4
#9 Search #1 OR #2
#8 Search #6 NOT #7
#7 Search animals [Mesh] NOT humans [Mesh]
#6 Search ((((((randomized controlled trial [pt]) OR controlled clinical trial [pt]) OR randomized [tiab]) OR placebo [tiab])
OR clinical trials as topic [mesh: noexp] OR randomly [tiab]) OR trial [tiab])
#5 Search Immediate OR rapid OR same-day OR “same day” OR fast-track OR “fast track” OR universal OR “test and treat”
OR early OR accelerat* OR instant OR prompt OR fast OR quick OR expedit*
#4 Search antiretroviral agents [Mesh] OR antiretroviral therapy, highly active [Mesh]
#3 Search Antiretroviral* OR ((anti) AND (retroviral*)) OR ARV* OR ART OR “antiretroviral therapy” OR HAART OR (
(highly) AND (active) AND (antiretroviral*) AND (therap*)) OR ((anti) AND (hiv)) OR ((anti) AND (acquired immun-
odeficiency)) OR ((anti) AND (acquired immuno-deficiency)) OR ((anti) AND (acquired immune-deficiency)) OR ((anti)
AND (acquired immun*) AND (deficienc*))
#2 Search HIV infections [MeSH] OR HIV [MeSH]
#1 SearchHIVORhiv-1ORhiv-2*ORhiv1ORhiv2ORhiv infect*ORhuman immunodeficiency virusORhuman immune
deficiency virus OR human immuno-deficiency virus OR human immune-deficiency virus OR ((human immun*) AND
(deficiency virus)) OR acquired immunodeficiency syndromes OR acquired immune deficiency syndrome OR acquired
immuno-deficiency syndrome OR acquired immune-deficiency syndrome OR ((acquired immun*) AND (deficiency syn-
drome)) OR HIV/AIDS
Embase (Ovid)
--------------------------------------------------------------------------------
1 *Human immunodeficiency virus/
2 *Human immunodeficiency virus infection/
3 (human immunodeficiency virus or human immune deficiency virus or human immuno-deficiency virus or human immune-deficiency
virus).ab.
4 (human immunodeficiency virus or human immune deficiency virus or human immuno-deficiency virus or human immune-deficiency
virus).ti.
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5 (hiv-1* or hiv-2* or hiv1 or hiv2).ti. or (hiv-1* or hiv-2* or hiv1 or hiv2).ab.
6 (HIV or HIV AIDS).ti. or (HIV or HIV AIDS).ab.
7 (acquired immunodeficiency syndromes or acquired immune deficiency syndrome or acquired immuno-deficiency syndrome or
acquired immune-deficiency syndrome).ti. or (acquired immunodeficiency syndromes or acquired immune deficiency syndrome or
acquired immuno-deficiency syndrome or acquired immune-deficiency syndrome).ab.
8 (acquired immun* and deficiency syndrome).ti. or (acquired immun* and deficiency syndrome).ab.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 *antiretrovirus agent/
11 *highly active antiretroviral therapy/
12 (ARV* or ART or “antiretroviral therapy” or HAART or (highly and active and antiretroviral* and therap*)).ti. or (ARV* or ART
or “antiretroviral therapy” or HAART or (highly and active and antiretroviral* and therap*)).ab.
13 ((highly and active and antiretroviral* and therapy) or (highly and active and antiretroviral* and therapeutic)).ti. or ((highly and
active and antiretroviral* and therapy) or (highly and active and antiretroviral* and therapeutic)).ab.
14 ((anti and hiv) or (anti and acquired immunodeficiency)).ti. or ((anti and hiv) or (anti and acquired immunodeficiency)).ab.
15 ((anti and acquired immuno-deficiency) or (anti and acquired immune-deficiency) or (anti and acquired immun* and deficienc*)).ti.
or ((anti and acquired immuno-deficiency) or (anti and acquired immune-deficiency) or (anti and acquired immun* and deficienc*)).ab.
16 10 or 11 or 12 or 13 or 14 or 15
17 9 and 16
18 (immediate or rapid or same-day or “same day” or fast-track or “fast track” or universal or “test and treat” or early or accelerat* or
instant or prompt or fast or quick or expedit*).ti. or (immediate or rapid or same-day or “same day” or fast-track or “fast track” or
universal or “test and treat” or early or accelerat* or instant or prompt or fast or quick or expedit*).ab.
19 17 and 18
20 random*.ti. or random*.ab.
21 placebo.ti. or placebo.ab.
22 (double-blind or “double blind”).ti. or (double-blind or “double blind”).ab.
23 randomized controlled trial/
24 *controlled clinical trial/
25 20 or 21 or 22 or 23 or 24
26 19 and 25
Web of Science - Core Collection
Science Citation Index Expanded (SCI-EXPANDED) --1970-present
Social Sciences Citation Index (SSCI) --1970-present
Conference Proceedings Citation Index- Science (CPCI-S) --1990-present
# 7 #6 AND #5
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
# 6 TITLE: (“randomized controlled trial” OR “randomised controlled trial” OR “controlled clinical trial” OR random* OR
placebo OR double-blind OR “double blind” OR single-blind OR “single blind”)
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
# 5 #4 AND #3
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
# 4 TOPIC: (Immediate OR rapid OR same-day OR “same day” OR fast-track OR “fast track” OR universal OR “test and treat”
OR early OR accelerat* OR instant OR prompt OR fast OR quick OR expedit*)
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
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(Continued)
# 3 #2 AND #1
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
# 2 TOPIC: (antiretroviral OR ART OR HAART OR “highly active antiretroviral*” OR ARV)
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
# 1 TOPIC: (HIV* OR “HIV infect*” OR “human immunodeficiency virus”) OR TOPIC: (AIDS OR HIV/AIDS OR “acquired
immunodeficiency”)
Indexes=SCI-EXPANDED, SSCI, CPCI-S Timespan=All years
Cochrane Central Register of Controlled Trials
Issue 8 of 12, August 2018
#1 HIV or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human immunodeficiency virus or human immune deficiency virus or
human immuno-deficiency virus or human immune-deficiency virus:ti,ab,kw (Word variations have been searched)
#2 (human immun*) and (deficiency virus) or acquired immunodeficiency syndromes or acquired immune deficiency syndrome or
acquired immuno-deficiency syndrome or acquired immune-deficiency syndrome:ti,ab,kw (Word variations have been searched)
#3 acquired immun* and deficiency syndrome
#4 “HIV/AIDS”
#5 MeSH descriptor: [HIV] explode all trees
#6 MeSH descriptor: [HIV Infections] explode all trees
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Anti-Retroviral Agents] explode all trees
#9 MeSH descriptor: [Antiretroviral Therapy, Highly Active] explode all trees
#10 antiretroviral*
#11 anti and retroviral*
#12 ARV* or ART or “antiretroviral therapy” or HAART
#13 highly and active and antiretroviral* and therap*
#14 anti and hiv
#15 anti and “acquired immunodeficiency”
#16 anti and “acquired immuno-deficiency”
#17 anti and “acquired immune-deficiency”
#18 anti and “acquired immun*” and deficienc*
#19 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 #7 and #19
#21 Immediate or rapid or same-day or “same day” or fast-track or “fast track” or universal or “test and treat” or early or accelerat* or
instant or prompt or fast or quick or expedit*:ti,ab,kw (Word variations have been searched)
#22 #20 and #21
LILACS
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Search on : antiretroviral$ OR ARTOR ARVORHAART [Words] and rapid OR accelerat$ OR early OR fast OR immediate
[Words] and random$ OR trial OR blind$ OR control$ OR compar$ [Words]
Africa wide via Ebscohost 1990 to 2018
AB ( antiretroviral* OR ART OR ARV OR HAART ) AND TI ( rapid OR accelerate* OR fast OR immediate OR early ) AND (
random* OR trial OR control* OR blind* ) AND AB ( HIV* OR HIV/AIDS OR AIDS )
ClinicalTrials.gov
rapid OR early OR immediate OR accelerate OR fast | Interventional Studies | antiretroviral OR ART OR ARV OR HAART
WHO ICTRP
Title: (rapid OR early OR immediate OR accelerate OR fast) AND
Condition: (HIV OR HIV/AIDS) AND
Intervention: (antiretroviral OR ART OR ARV OR HAART)
Recruitment status: All
Appendix 2. Study eligibility form
Review title or
ID
Study ID
Report ID
Date form com-
pleted (dd/mm/
yyyy)
Study
characteristics
Eligibility criteria Eligibility criteria met? Location in text or source (page and para-
graph/fig/table/other)
Yes No Unclear
Type of study Randomized controlled
trial or cluster-random-
ized trial
Participants HIV positive adults,
adolescents, children or
pregnant women tak-
ing antiretroviral ther-
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(Continued)
apy (ART) for their own
health
Types of inter-
vention
Rapid ART (defined as
receiving antiretroviral
therapy within 7 days
of HIV diagnosis) plus
usual care (for example,
counselling,
opportunistic infection
screening)
Types of com-
parison
Delayed ART (defined
as receiving antiretrovi-
ral therapy at any time
after 7 days post-HIV
diagnosis) plus usual
care
Types of out-
come measures
Viral suppression at 12
months and/or renten-
tion in care at 12
months and/or uptake
of ART and/or inci-
dence of IRIS and/or
incidence of regimen
change
INCLUDE (Yes/
No):
EXCLUDE (Yes/No):
Reason for exclu-
sion
Notes:
C O N T R I B U T I O N S O F A U T H O R S
AMU, RS, IEW, and SJ screened studies, extracted data, analysed results, and contributed to the writing of the review.
JBN contributed to the design of the review, provided input on analysis and interpretation of the results, and contributed to writing
the review.
All review authors responded to the referee comments and approved the final review version.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We defined rapid ART as offering ART to people living with HIV within seven days of diagnosis. In our review, however, we included a
study that aimed to offer ART within 14 days of diagnosis (Amanyire 2016). We performed a subgroup analysis to examine the effects
of starting ART within seven days compared with 14 days.
We did not specify in the protocol, but we also excluded studies that offered ART in the context of pre-exposure or post-exposure
prophylaxis.
During the review process, we identified significant variation in study design; as such we conducted a subgroup analysis to examine the
effect of cluster-designed RCTs.
In the protocol we stated that, to measure retention in care at 12 months, we would use results within the range of 6 to 14 months.
However, we also included data from a study that reported retention in care between 5 and 10 months (Rosen 2016), because it was
not possible to differentiate which participants fell into the 6- to 10-month range.
RS joined the review author team.
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